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Current management of asthma is based on assessment of symptoms and spirometry
to guide treatment. Measures of airway inflammation (AI) may lead to more
appropriately targeted anti-inflammatory therapy. However, there is debate as to
which markers are most useful and this is perpetuated by the lack of a gold standard
measure of bronchial inflammation, the lack of direct comparisons for multiple
markers in the same individuals, and the relative paucity of longitudinal studies. The
aim to this thesis was to investigate the clinical utility of contrasting biophysical,
biochemical and cellular markers ofAI in stable persistent and acute asthma.
Respiratory heat and moisture loss (RHML) is proposed as a novel biophysical
marker ofAI. In a cross-sectional study of 32 patients with stable asthma, 25 patients
with acute asthma and 25 controls, RHML was measured and compared against other
proposed inflammatory markers [the exhaled gases nitric oxide (NO) and carbon
monoxide (CO), exhaled breath condensate (EBC) pH and nitrite and sputum
eosinophil percentage], RHML was significantly elevated in stable asthma (p = <
0.01) and correlated with sputum eosinophil percentage (r = 0.73 ; p = < 0.01).
Paradoxically, RHML was not elevated in acute asthma, and a number of possible
explanations are discussed. Exhaled NO was significantly higher in stable asthma
compared with controls (p = < 0.01) and EBC pH was significantly lower in stable
asthma than controls (p = < 0.05). There was a further decrease in EBC pH in acute
asthma (p = < 0.01). Sputum eosinophil percentage was elevated in acute asthma,
compared with stable asthma (p = < 0.05). Exhaled CO and EBC nitrite were not
elevated in stable or acute asthma.
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To investigate the sensitivity of these markers to short term changes in AI, serial
measurements were made during the resolution of an acute exacerbation of asthma.
Exhaled NO decreased and EBC pH increased by day 7-9 of an exacerbation. In
addition RHML decreased between day 3-5 and day 7-9 of an exacerbation. The
changes in these markers lagged behind changes in FEVi, suggesting that AI persisted
beyond the principal period of bronchoconstriction.
The day-to-day repeatability of RHML, exhaled NO, EBC pH and nitrite was tested
with repeat measurements in patients with stable asthma. Repeated measurements of
RHML, exhaled NO and EBC nitrite were reproducible. However, EBC pH
measurements were highly variable.
In summary: 1) RHML is elevated in stable asthma and correlates with sputum
eosinophil percentage; 2) Exhaled NO is elevated in stable and acute asthma and
decreased during the resolution of an asthma exacerbation; 3) EBC pH is decreased in
stable, to a greater extent in acute asthma and increased as an exacerbation resolved;
however its intra-subject repeatability is poor; and, 4) In sputum, eosinophil
percentage is elevated in acute asthma compared with stable asthma.
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NON-INVASIVE ASSESSMENT OF AIRWAY
INFLAMMATION IN ASTHMA
INTRODUCTION
Despite the range of effective available treatments, asthma remains a significant
health burden, accounting for around 71,000 hospital admissions and 1,400 deaths per
year in the UK [1], Approximately 8% of the UK adult population have a diagnosis of
asthma, a figure which may be an underestimate as the prevalence of asthma
symptoms is far greater (up to 25% of the population [2]). This indicates that there is
considerable room for improvement in the assessment of asthma activity in guiding
the appropriate use of the available treatments.
The aims of asthma treatment are to:
• Achieve and maintain control of symptoms
• Prevent asthma exacerbations
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• Maintain pulmonary function as close to normal levels as possible
• Maintain normal activity levels, including exercise
• Avoid adverse effects from asthma medications
• Prevent development of irreversible airflow limitation
• Prevent asthma mortality [2]
Using measurements of airway inflammation to rationalise treatment decisions is
proposed as a way of helping to achieve these goals. A key component of such an
approach is the facility to detect and quantify airway inflammation easily and
harmlessly, allowing informed decisions about treatment to be made.
Asthma is usually described as recurrent episodes of wheezing, coughing, chest
tightness and shortness of breath particularly at night or early in the morning. Modern
definitions of asthma make clear reference to the underlying pathology that causes
these symptoms which is characterised by chronic airway inflammation [3], The
evidence that airway inflammation is pathological hallmark in asthma comes from
studies of bronchial biopsies [4], bronchoalveolar lavage [5], induced sputum [6] and
post-mortem studies of patients who have died as a result of acute asthma [7],
Indices of airway inflammation are not measured routinely in asthmatic populations.
Peak expiratory flow rate (PEFR) and sometimes spirometry are used as objective
measures to assist decisions regarding treatment. These are measures of airway
calibre, which change in relation to airway inflammation, but these changes may also
result from smooth muscle contraction or airway remodelling. The most direct
assessment of mucosal airways inflammation can be made with bronchoscopy and
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biopsy or broncho-alveolar lavage (BAL). However, this is invasive and clearly not
suitable for repeated measures in an individual patient. Out with a research setting,
this technique has limited clinical utility. The clinical need for non-invasive markers
of airway inflammation is the driving force behind this rapidly expanding area of
research.
The nature of the underlying inflammation in asthma is complex, with a large number
of inflammatory pathways involved [8]. Asthma is also increasingly recognised as a
heterogeneous inflammatory disorder where the type and degree of inflammation vary
[9-11]. Examples of proposed asthma phenotypes that vary in their response to
treatment and natural history are those with early onset of symptoms and atopy, who
behave differently from asthmatic patients that are obese and have predominantly
non-eosinophilic inflammation [12], The former group tend to respond readily to
treatment with inhaled corticosteroids, whereas the latter have a more limited
response to treatment. The variability within our current clinical definition of asthma
is very relevant in the context of developing an inflammatory marker or combination
of markers that provide useful information to guide treatment. This is one reason why
assessment of airway inflammation remains one of the major challenges in asthma
research.
This thesis examines contrasting biophysical, biochemical and cellular approaches to
the non-invasive assessment of airway inflammation in acute and stable asthma.
Novel methods for assessing airway inflammation such as respiratory heat loss
measurement and breath condensate markers have been studied, in addition to other
more established markers, including exhaled nitric oxide and induced sputum cell
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counts. This chapter will review the background and current knowledge of the
markers of airway inflammation that are investigated in subsequent chapters of this
manuscript, namely:
• Respiratory heat loss
• Exhaled nitric oxide
• Exhaled carbon monoxide
• Exhaled breath condensate pH
• Exhaled breath condensate nitrite
• Induced sputum differential inflammatory cell counts
RESPIRATORY HEAT LOSS
Inflammation is a complex process. However the gross changes that occur as a result
of inflammation have long been recognised in the classic description of inflammation
as rubor, calor, dolor and tumor. Measurement of respiratory heat loss is a novel
application of this established definition that may provide a quantitative measure of
airway inflammation. It is based on the hypothesis that increased vascularity and
vasodilatation associated with inflammation will lead to a measurable increase in heat
loss.
During normal respiration, a counter current mechanism for respiratory heat transfer
operates [13]. As air is inspired, it is heated and humidified, resulting in cooling and
8
drying of the airway mucosa. By the time air reaches the alveoli it is at body
temperature and fully saturated with water. During expiration, a variable proportion
of this heat energy is regained by the conditioned mucosa as air exits the lung. The
result is net heat loss. Conditioning of inspired air is dependent on a source of heat
and water that comes from airway mucosal blood flow. In asthma, it is proposed that
changes in airway mucosal blood flow associated with airway inflammation will
result in altered conditioning of inspired air and lead to changes in net heat loss.
Factors That Affect Measurement ofRespiratory Heat Loss
Measurement of respiratory heat loss is challenging. Heat is lost from the respiratory
tract not only by convection, but also by evaporation. The latter is the dominant
means of heat transfer in the respiratory tract [14]. To quantify total respiratory heat
loss accurately, both the temperature and water content of expired air must be taken
into account. Furthermore, respiratory pattern and inspired air conditions affect
respiratory heat loss and must be controlled.
During normal tidal breathing in ambient room air conditions, the majority of heat
transfer takes place in the upper respiratory tract [15]. When ventilation rises or
inspired air temperature is lowered, unconditioned air passes deeper into the thoracic
airways such that deeper generations of bronchi become involved in air conditioning
[16]. This results in greater net respiratory heat loss. Therefore, to detect an
alteration in respiratory heat exchange as a result of sub-glottic airway inflammation it
is necessary to either increase the respiratory rate or tidal volume, or to reduce the
temperature and water content of the inspirate. Unfortunately, these manoeuvres may
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also alter the airway environment, by changing airway calibre or altering mucosal
blood flow. In fact, the main focus of research into respiratory heat exchange in
asthma has been the effects of extreme ventilatory conditions on the airway as a
model for exercise or cold air induced asthma [17]. In designing apparatus to measure
respiratory heat flux in the lower airway, a ventilatory condition must be found that
engages the lower airways in heat exchange without itself altering the airway structure
or function.
Out with the airway itself, the core body temperature of an individual should be taken
into account. An increase in core body temperature is reported to result in an increase
in respiratory heat loss [18]. Although this may be predominantly due to an increase
in minute ventilation, it may be of relevance in studying patients with acute disease,
where there may be associated pyrexia in the presence of infection.
Relationship between Respiratory Heat Loss and Airway Inflammation
A hallmark of airway inflammation is increased mucosal vascularity. In asthma, this
has been demonstrated in bronchial biopsy studies and using non-invasive gas
diffusion techniques. Biopsy studies have demonstrated greater vascularity in
asthmatic bronchial mucosa [19-21]. This has also been demonstrated visually using
high magnification videobronchoscopy [22], Using a soluble gas uptake method to
measure airway mucosal blood flow, greater magnitudes of blood flow have been
estimated in steroid naive and steroid treated asthmatic patients compared with
controls [23], Using the same method, mucosal blood flow is reported to decrease
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following treatment with an inhaled corticosteroid in individual asthmatic patients
[24],
These structural changes in the vascularity of the airway mucosa associated with
airway inflammation may lead to changes in respiratory heat flux. Paredi et al have
reported a faster rise in breath temperature during expiration in asthmatics compared
with controls [25], Although only convective heat losses were measured in this study
and subjects were breathing ambient room air, it suggests that changes in
inflammation may alter heat transfer in the asthmatic airway. However,
measurements of convective heat loss by breath temperature alone do not provide an
accurate indication of total heat loss as they do not take heat loss via evaporation into
consideration. This has been demonstrated in intubated patients where measurements
of tracheal temperature do not accurately predict total respiratory heat losses [26].
McCafferty et al have reported an increase in total respiratory heat loss in asthmatic
patients compared with controls [(27); figure 1], using a device that incorporates
measurements of both convective and evaporative heat loss, and uses a conditioned
cool, dry air to engage the lower airway in heat exchange. The temperature of
inspired air used in the protocol was 7 °C, and a target minute ventilation of 15 L/min,
with a tidal volume of 1.5 L was used. This represents a thermal burden of
approximately 25 Watts. This is around 10% of the values used in most studies to
induce a change in FEVi, and equivalent to those found not to change bronchial blood
flow in normal subjects [28], In the study by McCafferty et al, breathing cold air did
not appear to cause bronchoconstriction; no changes in FEV i were observed using the
protocol described.
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Figure 1: RHML in Joules / L of ventilation in asthmatics and healthy controls.
Means ± 95% confidence intervals are denoted by error bars. P-values based on
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These preliminary results raise the tantalising prospect that calor, one of the classical
signs of inflammation may be measured in exhaled breath and provide a non-invasive
means of assessing airway inflammation in asthma. In this thesis, further
investigations were undertaken to seek confirmation of these observations and extend
them to investigate longitudinal changes in heat and moisture loss.
Exhaled nitric oxide has been promoted widely as a non-invasive marker of airway
inflammation in asthma. Nitric oxide was first identified in exhaled breath of animals
EXHALED NITRIC OXIDE
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and humans using chemiluminescence by Gustavsson et al in 1991 [29]. Soon after,
it was reported to be elevated in patients with asthma [30]. This finding has since
been confirmed many times in different centres across the world. At the time of
writing this review, there were over 700 citations for 'exhaled nitric oxide + asthma'
in a Medline search. The scale of research into exhaled NO reflects not only great
interest in its potential, but also problems that may limit its clinical application.
Nitric oxide is produced by nitric oxide synthase (NOS) which exists in two isoforms:
constitutive NOS (cNOS) and inducible NOS (iNOS). Both forms are present in
human airway tissue. However, the inducible form is capable of producing much
greater quantities of nitric oxide. Expression of iNOS is markedly increased in
asthma and is likely to be responsible for the elevated levels of exhaled NO seen in
asthma [31, 32]. NOS expression can be induced by a variety of stimuli, in particular
inflammatory cytokines although the exact mechanism in asthmatic airway
inflammation remains unclear.
Measurement of Exhaled Nitric Oxide
Efforts to standardise measurement of exhaled NO has led to the publication of
international guidelines that enable NO values to be compared across different centres
[33]. The guidelines cover both online measurement, where real-time recordings of
NO are made using a chemiluminescent technique, and offline measurement, where
exhaled air is collected in gas impermeable bags and measured later. The on-line
method, which we have used, has significant advantages including instant results and
greater control over measurement error.
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Factors that Affect Exhaled Nitric Oxide Concentration
Nitric oxide in exhaled breath is present in very low concentrations [up to 100 parts
per billion (ppb)]. There is therefore significant potential for sample contamination
and it is important to exclude other sources ofNO where possible. It is produced in
high quantities in the nose, which can effectively be excluded by using nose clips or
asking the subject to exhale against resistance such that mouth pressure exceeds 5
cmfhO, which is adequate to keep the soft palate closed [34], The mouth is also a
potential source of contamination. Exhaled NO from tracheostomised patients is
significantly higher during oral exhalation compared with tracheal exhalation [35].
This is more difficult to control and highlights the potential for contamination when
measuring very small concentrations of a volatile gas.
The effect of ambient NO on exhaled NO values is controversial. NO is present in the
atmosphere and concentrations fluctuate. Jobsis et el reported that high ambient
levels of NO correlate positively with exhaled NO, although an offline method was
used [36]. Ho et al examined peak and plateau NO levels on-line using high and low
levels of inspired NO and found that peak NO levels increased with high inspired NO
[37], Plateau levels were however unaffected, which suggests that any influence of
exogenous NO is small and may only affect the NO peak. To minimise any possible
effects of atmospheric NO, commercially available equipment allows a baseline of
ambient NO to be established or provides a supply ofNO-free air.
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Exhaled NO shows marked dependence on expiratory flow rate [38, 39]. At higher
flow rates, there is less time for diffusion ofNO into the airway lumen and a relative
reduction in exhaled NO. It is therefore important that expiratory flow rate is
controlled and when exhaled nitric oxide levels are reported, the expiratory flow rate
must also be expressed. In practice as long as the flow rate is clearly reported and
controlled between subjects using a suitable targeting system, the results can be
interpreted sensibly.
Despite controlling for exhalation flow rate, there is still great variability in both
control values and values for patients with asthma whether treated with inhaled
corticosteroids or not [(34, 39, 40, 42-47); table 1]. Some of this may be due to
differences in disease activity in the cohorts of patients with asthma that were studied,
but there are also numerous other factors that may affect exhaled NO concentration
and further explain the variability seen.
Exhaled NO is not a disease-specific marker for asthma. It has been reported in other
diseases or conditions that may co-exist with asthma. These include viral infections,
allergic rhinitis, atopy (without asthma), COPD, chronic cough, and pneumonia [48].
The presence of these conditions in asthmatic subjects can make the interpretation of
exhaled NO values very complex.
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Table 1. Normal adult values ofexhaled nitric oxide at exhalation flow rates of 50
ml/s and 250 ml/s (ICS — inhaled corticosteroid treatment). Values are median
(interquartile range) or mean ± SD.





Control (21) 50 6 (5-8)
[40]
Asthma (14) 50 14(8-25)
Kharitonov et al
Control (10) 50 17.8 ±6.8
[34]
Asthma (10) 50 48.8 ±27.2
Delen et al
Control (18) 50 11.1 ± 1.6
[42]
Asthma (42) 50 16.4 ± 1.3
Deykin et al Control (18) 250 8.4 ±0.7 [39]
Asthma (17) 250 16.0 ±2.0
Ojoo et al
Control (15) 250 9 ± 4
[43]
Asthma (12) 250 35 ± 19
Corradi et al
Control (10) 250 6.8 ±0.3
[44]
Mild asthma (9) 250 17.9 ± 1.8
Lim et al
Asthma (no ICS; 16) 250 9.9 ±3.5
[45]
Asthma (ICS; 16) 250 13.6 ±2.0
Gratziou et al
Control (100) 250 4.8 ±0.3
[46]








Lifestyle factors that may affect exhaled NO are diet and smoking status. Nitrate rich
diets increase NO [35]. Caffeine may also have some effect although results are
conflicting; it has been reported to both increase and decrease NO by modest amounts
[49, 50], Smoking is reported to reduce exhaled NO [51]. Most studies in asthma
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have excluded smokers, however in current clinical practice, a significant proportion
of asthmatic patients smoke.
Bronchoconstriction can decrease exhaled NO levels [52], This is probably a result of
increased air flow rate within the conducting airways to achieve the target exhalation
flow rate and a consequent reduction in NO diffusion time. This may be of relevance
in longitudinal studies where fluctuations in the airway calibre of individuals may
have an effect on measurements of exhaled NO.
Finally, in many studies, other markers of airway inflammation are measured
consecutively and it is worth noting that both spirometric manoeuvres and sputum
induction have been reported to decrease exhaled NO [53]. Therefore, these tests
should not be done before measuring exhaled NO.
Relationship between Exhaled Nitric Oxide and Airway Inflammation
Exhaled NO was originally proposed as a marker of airway inflammation following
the observation that elevated levels are present in asthma and decrease after anti¬
inflammatory treatment with inhaled corticosteroids [54, 55]. Further evidence of a
relationship between exhaled NO and mucosal inflammation has been sought in
bronchoscopic biopsy studies. However, studies of this nature have been limited due
to their invasiveness. Payne et al, have reported a correlation between an
endobronchial biopsy score of inflammatory components and exhaled NO in a small
cohort of children with difficult asthma who were treated with oral corticosteroids
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[56]. In adults, there are conflicting findings. Van der Toorn et al reported a
correlation between airway eosinophilia and exhaled NO [57], whereas, Lim et al
found no relationship between the two [45], Rather surprisingly, the former study
examined subjects with a history of asthma who were in clinical remission. However
both studies had small sample sizes, which highlights one of the disadvantages of
such an invasive technique. A further limitation of biopsy studies is that a small
sample from a discrete area of the bronchial tree is obtained, which may not reflect
the global state of airway inflammation within the bronchial tree. In contrast, most
non-invasive markers diffusely sample the airway, although the exact site of
production of the measured substance is sometimes unclear.
Exhaled NO has been reported to correlate with blood eosinophilia, sputum
eosinophilia, BAL eosinophilia and bronchial hyper-responsiveness in steroid naive
patients with asthma [58, 59], This relationship appears particularly pronounced in
atopic asthma [46]. In steroid-treated patients, the relationship is less clear [47, 60],
This may be a result of variable response to anti-inflammatory therapy with each
marker. In a double blind placebo controlled trial of inhaled steroid treatment in mild
asthma, van Rensen et al reported a decease in NO, a decrease in sputum eosinophilia
and an increase in the concentration of histamine provoking a fall in FEV i of 20% or
more [55]. There was no relationship to the changes in each of the three markers in
the groups at any time. Thus, although correlations in cross-sectional untreated
asthmatics may be apparent, the added complication of introducing disease modifying
treatment can disturb the relationship between different inflammatory markers as they
have a variable response to treatment.
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The effect of an increase in airway inflammation on exhaled NO has also been
studied. As steroid treatment suppresses airway inflammation, it is reasonable to
assume that stopping steroid treatment will lead to an increase in airway
inflammation. Jones et al have reported a significant increase in exhaled NO
following withdrawal of inhaled corticosteroid that is associated with loss of control
of asthma, defined as deterioration in symptoms or morning PEFR [61]. It may be
difficult to differentiate whether the increase in exhaled NO is due to an increase
inflammation or loss of a direct inhibitory effect of steroids on NO production. An
association with worsening asthma symptoms and a reported concomitant increase in
sputum eosinophils supports the notion the airway inflammation is increased [61]. In
addition, a proportion of asthmatics from the same study, that did not experience
worsening symptoms, had no increase in exhaled NO.
In the context of an asthma exacerbation, it is also reasonable to assume that airway
inflammation will be increased. An allergen-induced asthma exacerbation can be
simulated using allergen challenge testing in a controlled environment. Exhaled NO
has been shown to increase in the late response phase following allergen challenge
[62, 63]. However this finding was only present in asthmatics that were not on
regular inhaled or oral corticosteroids. In spontaneous exacerbations of asthma
exhaled NO is elevated and decreases following treatment with oral glucocorticoids
[64].
An increase in exhaled NO has been proposed as a predictor of future exacerbations
of asthma [61, 65], In a survey ofmoderate-severe asthmatics attending an outpatient
clinic, Harkins et al reported that those who had an exacerbation within two weeks of
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attending clinic had higher exhaled nitric oxide levels in clinic [65]. However, the
elevated NO levels may simply reflect severity of asthma and thereby a tendency to
exacerbate. In another controlled steroid reduction trial by Leuppi et al, exhaled NO
levels did not predict exacerbations, in contrast to sputum eosinophils and bronchial
hyper-responsiveness which did [66],
Smith et al have reported that exhaled NO is superior to conventional methods for
safely reducing the dose of inhaled corticosteroids [67]. In a single blind randomised
controlled study comparing the used of exhaled NO measurement against symptoms
and spirometry to adjust steroid dose, the exhaled NO group were on a significantly
lower doses of inhaled corticosteroid by the end of the year long study. There was no
difference in exacerbation rates between the two groups. However, more recently
Shaw et al have reported no benefit of a similar strategy using exhaled NO
measurements to guide reduction in corticosteroid dose [68].
Spirometry remains the standard objective test of asthma control. In general, exhaled
NO does not correlate strongly with spirometry. This should not detract from the
utility of exhaled NO as a marker of Al. The two tests could be regarded to be
examining different components of asthma pathophysiology. If markers of airway
inflammation all closely correlated with a straightforward test such as spirometry,
then there would be little point in measuring them.
The evidence that supports the use of exhaled NO as a marker of airway inflammation
is greatest in steroid nai've asthmatic patients. Exhaled NO may be elevated by
conditions other than asthma, is greatly suppressed by inhaled steroids, and its
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potential role in management of steroid-treated patients still needs further
clarification. In this thesis exhaled NO will be measured in patients with stable
asthma and acute exacerbations and compared with other non-invasive markers
EXHALED CARBON MONOXIDE
The notion that exhaled carbon monoxide levels may relate to airway inflammation
assumes that oxidative stress plays an important role in airway inflammation in
asthma. Carbon monoxide is produced by heme-oxygenase-1 (HO-1), an enzyme that
is up-regulated by inflammatory cytokines. HO-1 catabolises heme to bilirubin, free
iron, and carbon monoxide. It has been suggested that HO-1 serves a protective role
in response to stress [69]. CO stimulates guanylate cyclase, which is thought to have
a role in regulating inflammation, and another product bilirubin is an antioxidant.
Measurement of Exhaled Carbon Monoxide
Carbon monoxide in exhaled breath is measurable in real-time using an
electrochemical analyser or a non-dispersive infrared technique. One of the
attractions of exhaled CO is that it is present in much greater concentrations than
nitric oxide. Subjects are asked to perform a slow vital capacity manoeuvre at a
predetermined expiratory flow rate. Mean or end-tidal CO concentration is then
measured.
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Factors that Affect Exhaled Carbon Monoxide Concentration
The major confounding factor that limits use of exhaled CO is cigarette smoking,
including passive smoking. Smoking can greatly elevate exhaled CO concentrations
to several fold above the levels observed in non-smokers [70, 71]. Indeed exhaled CO
is sometimes used as a marker of smoking status. It could also be speculated that
environmental pollution would also lead to high exhaled CO levels, although evidence
to support this is lacking [72].
There does not appear to be the same dependence on exhalation flow rate as there is
with exhaled NO concentration [73]. However, levels are reported to increase
following a breath hold of ten seconds [71]. This is an important issue as it implies
that a significant proportion of exhaled CO may be from an alveolar source. Several
studies of exhaled CO have used a breath-hold technique and this should be taken into
account when interpreting the results.
Exhaled CO is not a specific marker of AI in asthma. It may be elevated in other
conditions, including upper respiratory tract infections, COPD and cystic fibrosis [74-
76],
Relationship between Exhaled Carbon Monoxide and Airway Inflammation
There are several reports of elevated breath CO levels in cross-sectional studies of
asthmatics and controls in children and adults. In adults, Horvath et al and Zayasu et
al, have reported that exhaled CO is elevated in mild untreated asthma but not in
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steroid treated asthma [77, 78], Yamaya et al have reported elevated exhaled CO
levels in severe asthma, but not in mild asthma [79], However, Zetterquist et al
reported no difference in exhaled CO concentration between patients with asthma and
controls [71]. In children, there is a similar conflicting picture in the two published
studies examining exhaled CO. One study reports elevated CO in steroid naive
asthma [73] and the other reports no elevation in mild untreated asthma, but a
significant increase in exhaled CO in persistent asthma on inhaled corticosteroids
[71].
The reasons for the different findings may be due to differences in the spectrum of
'mild' asthma. Definitions of asthma severity are based on symptoms, level of
treatment and spirometry, and they may not necessarily reflect the underlying state of
Al. Another possible explanation is that patients with more severe or persistent
asthma have more distal airway inflammation, and alterations in exhaled CO become
apparent only when a breath hold manoeuvre is used. In the studies that have reported
an increase in exhaled CO in steroid-treated asthma, a breath hold protocol was used
[74, 79],
Longitudinal changes in exhaled CO following treatment with corticosteroids have
been investigated. In mild asthma, a randomised double blind placebo controlled trial
of inhaled corticosteroid treatment failed to demonstrate any change in exhaled CO in
the treatment or placebo arms [80]. However in acute asthma exhaled CO has been
reported to increase from baseline levels and then decrease following treatment with
oral corticosteroids [81]. Different methods used in these two studies make it difficult
to draw firm conclusions. In the study of mild asthmatics, a slow vital capacity
23
manoeuvre was used to measure exhaled CO. However, in the acute asthma study, a
twenty second breath hold was followed by a rapid exhalation. The longitudinal
changes observed in acute asthma appear convincing, although the baseline values of
exhaled CO are low in comparison with other studies using a breath hold manoeuvre.
The response of exhaled CO to controlled allergen challenge has been studied. Paredi
et al, have reported that exhaled CO increased in both the early and the late phase
response to allergen challenge [81]. However, Khatri et al, have reported that exhaled
CO decreased in the early phase and returned to baseline in the late phase [82], The
latter study used a 15 second breath hold and an off-line technique, and failed to
demonstrate any difference in exhaled CO between the asthmatic patients studied and
control subjects at baseline measurements. The study populations may be different as
Paredi et al reported a significant elevation of baseline exhaled CO in their asthmatic
group.
Correlations between exhaled CO and other markers of airway inflammation or
pulmonary function are inconsistent. As with other non-invasive markers of
inflammation, this may be due to different pathways of inflammation involved and
variable response to anti-inflammatory treatment.
Investigators have attempted to demonstrate alterations in levels of HO-1, the likely
source of CO production. Horvath et al have reported that respiratory macrophages
from induced sputum of steroid naive asthmatics have an up-regulation of HO-1 in
association with an increase in exhaled CO [77]. However, Lim et al reported no
difference in expression of HO-1 in bronchial biopsies between asthmatic and control
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subjects and no change after four weeks of inhaled steroid treatment, although airway
eosinophils and exhaled NO decreased [45],
There is no clear consensus as to the utility of exhaled carbon monoxide in assessing
airway inflammation in asthma. Although it is present in greater concentrations than
NO, the proportional fluctuations in levels seen are significantly less. The data
available regarding exhaled CO are difficult to interpret due to different protocols for
measurement and inadequate characterisation of asthmatic populations in some
studies. Guidelines for measurement of exhaled NO have greatly assisted cross-study
comparisons and similar guidelines for the measurement of exhaled CO would help
progress research in this area. The key factors in measuring exhaled CO are that it is
only of value in non-smokers and a breath-hold is not be recommended as this is
likely to increase exhaled CO due to increased time for diffusion of CO in the alveoli.
The exhalation flow rate does not appear to be important in determining exhaled CO,
in contrast with exhaled NO. In this thesis exhaled CO is examined in stable asthma
and during an acute exacerbation of asthma, in addition to other inflammatory
markers.
EXHALED BREATH CONDENSATE
Exhaled breath condensate collection has been proposed as a convenient and non¬
invasive method of sampling airway lining fluid, which contains molecules that may
be used as biomarkers of airway inflammation. Although a wide range of molecules
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have been measured in EBC, none have yet been clinically validated. There is
significant variability of results due to difficulty in standardising methods of
collection and analysis, and also possibly intrinsic sample-to-sample variability.
Collection Methods
Breath condensate is collected by cooling expired gas in a cold air trap, allowing
moisture to condense and collect in a reservoir (figure 2). Typically, 1-3 ml of breath
condensate can be collected from ten minutes of tidal breathing, using a cold trap at
-20 °C. Prevention of saliva contamination can be achieved by using a saliva trap and
asking subjects to maintain a "dry" mouth and swallow any saliva that accumulates.
Amylase assays may be used to confirm the absence of salivary contamination. Nose-
clips are worn during EBC collection to prevent nasal contamination from nasal
inhalation and to ensure that all exhaled air exits through the mouth.








The efficiency of current methods of collecting breath condensate is approximately
30-40%, depending on the ventilatory pattern. An increase in minute ventilation,
reducing the inspired air temperature will yield a greater volume of breath condensate,
while the concentration of solutes appears to be unaffected in healthy control subjects
[83].
Factors that Affect Exhaled Breath Condensate Markers
Measurement of substances in EBC has problems with poor reproducibility and
inconsistency between different research centres [84]. The most likely explanation
for this is a combination of extremely dilute samples [> 99% water vapour; (85)] and
poor sensitivity ofmany of the commercially available assays that have been used to
measure molecules in EBC. Many of the substances that have been measured in EBC
are near the bottom of the standard curve for commercially available assays and
therefore results must be interpreted with caution.
Effros et al have suggested that the use of an internal standard as a dilution marker
can lead to greater reproducibility [86]. This proposal is based on the assumption that
concentrations of certain substances in airway lining fluid have a steady relationship
with plasma levels, such as urea, sodium and chloride. However, the assumption that
airway lining fluid and plasma have the same osmolality should not be taken for
granted, particularly in disease states. In exercise induced asthma, an increase in
mucosal osmolality due to dehydration may be the trigger for mast cell degranulation
and mediator release [87], A further complication is that a large sample (several
millilitres) is required to measure potassium and sodium levels, which is time
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consuming to collect. Conductance measurements correlate well with sodium and
potassium concentrations of lyophilized (freeze-dried) EBC and may provide an
alternative internal standard for estimating dilution [86]. However, lyophilization
removes volatile substances that may be of interest in EBC, such as ammonia.
There is also debate as to the exact site of origin of droplets in EBC from the
respiratory tract [35]. There is little doubt that EBC contains compounds that have
originated in the lower respiratory tract, and the characteristics of EBC are markedly
different from saliva [88]. However air must pass in and out through the upper
respiratory tract which will also contribute to the make-up of the condensate.
Differences in concentrations of nitrite have been reported in tracheostomised patients
during mouth and tracheal breathing [35],
The American Thoracic Society/ European Respiratory Society Taskforce on Exhaled
Breath Condensate have published recommendations for collection, storage and
assays of EBC [89], However, it is recognised that there is great diversity in EBC
(numerous different molecules that can be measured and variable assay techniques)
and therefore the recommendations were largely limited to general guidance on
standardising collection methods. EBC should be collected during tidal breathing
using a nose-clip and the collection time and cooling temperature should be recorded.
Exhaled Breath Condensate Nitrite
Under physiological conditions, nitric oxide is unstable and reacts readily with
oxygen to form the relatively stable soluble metabolites, nitrite (NO2") and nitrate
(NO3"). Nitrite can be measured in EBC using a colorimetric assay based on the
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Greiss reaction [90]. However in EBC, nitrite is found in the lpM range which is
close to the detection limit for most assays.
As exhaled NO is elevated in asthma, one would expect that one of its metabolites,
nitrite, would also be elevated in EBC. Indeed, nitrite and nitrate have been reported
to be elevated in asthma in adults and children [91-93]. The levels may also decrease
after treatment with corticosteroids. In a randomised controlled trial, Kharitonov et al
reported that total nitrite and nitrate decreased following treatment with inhaled
corticosteroids in mild asthma [80]. However, a study by Ojoo et al found no
difference in EBC nitrite or nitrate in asthma compared with controls [43]. Further
studies in cystic fibrosis (CF) suggest that the relationship between exhaled NO and
EBC nitrite is not straightforward. Ho et al have reported that EBC nitrite levels are
elevated in CF breath condensate, in contrast to exhaled NO, which is not different
from controls [32]. Thus, elevated NO levels are not necessarily associated with
elevated metabolites ofNO in breath condensate.
Exhaled breath condensate pH
Hunt et al have reported that EBC from patients with acute asthma is acidic and the
pH increases after treatment with steroids [94], Potential implications of reduced
airway pH in acute asthma are bronchoconstriction and decreased ciliary activity
leading to mucous plugging and accelerated eosinophil necrosis [94], In stable
asthma, Kostikas et al have found a reduced pH, although only in patients with
moderate persistent asthma and not in patients with mild asthma [95]. This study also
reported more marked reductions in pH levels in COPD and cystic fibrosis, and
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correlations between sputum neutrophil percentage and EBC pH, suggesting that
neutrophilic inflammation may contribute to a reduced airway pH. In asthma,
neutrophils are felt to be important in exacerbations [96, 97] and severe disease [98].
Another factor facilitating airway acidification in asthma may be a reduction in
expression of glutaminase, which has the ability to buffer changes in extracellular pH
by releasing ammonia. Hunt et al have demonstrated attenuated activity of
glutaminase in epithelial cells following treatment with pro-inflammatory cytokines,
interferon gamma (IFN-y) or tumour necrosis factor alpha [TNF-a; (99)].
There is debate about the source of EBC acidification. Vaughn et al have reported
that in control subjects, 30/32 subjects had minimal or no difference in the EBC pH
obtained from oral collections and isolated lower airway collections [100]. However,
airway acidification has not been confirmed invasively with bronchoscopy in airway
disease. In acute lung injury, bronchial lining fluid pH and EBC pH does not
correlate well [101]. EBC ammonia may be relevant as it forms an alkaline solution
which may act as a buffer to acidic EBC. There is a significant decrease in EBC
ammonia after intubation and after mouth rinsing, which suggests that a significant
proportion of ammonia comes from the upper respiratory tract [35]. Interestingly
EBC ammonium is reported to be lower in children with asthma than control subjects
[102]. One study that examined the effect of ammonia removal found no effect on












































Breath condensate markers have provided great interest as potential markers of airway
inflammation. However they have also been subject to debate as the source of breath
condensate markers is unclear and the samples that are collected are extremely dilute,
and may be variably dilute. The proposed origin of the EBC markers discussed in this
thesis is summarised in figure 3. There are now guidelines for the methods of EBC
collection, although the use of an 'internal standard' to correct for dilution remains
controversial and further evidence is required before this will become standard
practice. Further studies are required to validate EBC pH and nitrite as markers of
airway inflammation in asthma. In this thesis, the behaviour of breath condensate
markers will be studied in parallel with other markers ofAI in stable asthma and acute
disease.
INDUCED SPUTUM DIFFERENTIAL EOSINOPHIL COUNTS
Induced sputum collection using nebulised hypertonic saline was first advocated by
Pin et al in 1992 [104], Prior to this spontaneously expectorated sputum had been
investigated, but was felt to be unreliable as it was not always available, and cells
were difficult to identify in the unprocessed, whole sputum. The use of hypertonic
saline to 'induce' sputum production made samples collected more reliable, with
increased viability of cells [105], and subsequent advances in processing sputum has
established its key role in research into airway inflammation. In contrast to EBC,
sputum provides a concentrated sample of cells, proteins and other metabolites.
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Method of Collection
The methods used to induce sputum vary between centres, but all share important
characteristics. There is always pre-treatment with a bronchodilator, usually a beta-2-
agonist is used to guard against bronchoconstriction, and inhalations of hypertonic
saline are delivered via an ultrasonic nebuliser, usually in incremental concentrations
that range from 3-5% [106], Bronchodilation is generally effective although some
breakthrough bronchoconstriction may still occur. Nevertheless, sputum induction is
widely regarded as a safe procedure. Hypertonic saline is used as it is reported to
enhance mucociliary clearance [107] and stimulate a cough response [108]. It results
in greater quantities of sputum compared with normal saline, although samples are
qualitatively the same [109], Successful sputum collection also depends on intrinsic
factors such as the degree ofmucous secretion in an individual.
After collection sputum can be separated from saliva and divided into a cellular
compartment to make cytospins for calculation of differential cell counts and
supernatant for examination of extracellular proteins [110]. Cell differentials and
supernatant protein markers are reported to be acceptably reproducible using this
technique [111].
Factors that Affect Induced Sputum Markers
Induced sputum is presumed to originate from the lower airway. However Keating et
al reported that eosinophil and neutrophil percentages are higher in sputum than in
bronchial washings or BAL fluid [112]. In the same study, the proportions of
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inflammatory cells in sputum correlated with bronchial washings, but not with BAL
fluid and the authors therefore concluded that induced sputum reflects inflammation
within the proximal airway.
There will be a proportion of patients (20-30%) in whom an adequate sample is not
obtained. The quality of a sample is determined by the volume of sputum obtained
and the proportion of squamous cells in the sample (usually < 20%). Using a
selected portion of the sputum sample, that is felt to originate from the lower airway
reduces contamination with saliva and squamous cells to a variable extent [113]. This
is usually done using forceps to extract the solid components of a sputum sample. The
variable contamination and dilution of sputum samples means that inflammatory cells
are usually reported as a percentage rather than an absolute number. However this
approach could potentially lead to an under or over-estimation of the degree of
inflammation, depending on the total number of inflammatory cells present. For
example, in the presence a large number of neutrophils in sputum, eosinophils may
also be elevated, but the percentage may appear low due to an abundance of
neutrophils.
The quality of the sample may also be affected by the time between sputum collection
and processing. A sample processing time of < 2 hours is recommended to maintain
the viability of cells within the sample. However one study suggests that cell viability
is acceptable up to 9 hours after collection in refrigerated samples [114].
Despite the potential variability of the induced sputum samples, differential
inflammatory cell percentage appears to be a reproducible measurement. There is
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good between observer repeatability of cell counts [115], Furthermore, the within
sample repeatability and day-to-day repeatability of cell percentages from induced
sputum samples in healthy controls and mild asthma is reported to be good [116], as
is the day-to-day repeatability in moderate-severe asthma [116, 117]. However within
a 24 hour period, Nightingale et al have reported that serial induced sputum samples
from healthy controls are not reproducible. The percentage neutrophils increases and
percentage macrophages decreases after the first sample [118]. This finding has been
confirmed by other authors and it is proposed that the process of sputum induction
stimulates some mild AI [119].
Induced Sputum Eosinophil Percentages and Airway Inflammation
Sputum, due to its abundance of cells, proteins and other metabolites has widespread
applications for investigating airway inflammation. The protein rich supernatant can
be used to study extracellular markers of inflammation. However, the most widely
used biological marker from induced sputum in asthma is the differential eosinophil
cell count.
The proportion of eosinophils in sputum from asthmatics is elevated compared with
controls. This is in keeping with the presence of BAL eosinophilia in asthmatics
[112, 120], Sputum eosinophilia is present in most cases of untreated or uncontrolled
asthma and is suppressed by treatment with corticosteroids, which is associated with
an amelioration of symptoms and an improvement in spirometry [121]. The presence
of sputum eosinophilia can predict response to corticosteroid treatment [122], and the
absence of sputum eosinophilia can identify a subgroup of patients who will not
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respond well to steroid treatment. Pavord et al have reported no change in bronchial
hyper-responsiveness in non-eosinophilic asthma (sputum eosinophils < 3%) in
contrast with an eosinophilic asthma group who had an increase in PC20 following
treatment with inhaled corticosteroids [budesonide 800 meg/ day; (123)].
At odds with this is the observation that in severe asthmatics with persistent airflow
limitation, there is still significant sputum eosinophilia, despite high doses of inhaled
corticosteroids [124], However, a subsequent study by the same group has found that
this apparent resistance to the effects of high dose inhaled steroids or oral
corticosteroids may be overcome with high dose systemic corticosteroid delivered by
intramuscular injection [125], This may represent a relative resistance to steroid
treatment in severe persistent asthma, although delivering steroids by a long-acting
injection also overcomes any problems that there may be with compliance with
inhaled/ oral steroids.
Eosinophils are likely to play an important role in the development of asthma
exacerbations. In a steroid reduction trial, sputum eosinophilia was reported to be a
good predictor for loss of control of asthma [126]. However, the number of patients
in this study was small and only seven subjects developed a loss of control of their
asthma symptoms. Furthermore, the study did not use a blinded protocol.
The most compelling evidence for the use of induced sputum eosinophil cell counts in
asthma is from a randomised controlled trial comparing treatment based on sputum
eosinophil cell counts alone against treatment decisions based upon BTS guidelines
for asthma management [127], The patients studied all had moderate or severe
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persistent asthma. The primary outcome was exacerbation rate. Patients in the
induced sputum management group had a highly significant reduction in the number
of exacerbations. There was no difference the dose of corticosteroids used in each
group. In support of this study, a reduction in asthma exacerbation rate using
strategies base on controlling sputum eosinophils percentage has subsequently been
reported in two further randomised controlled trials [96, 128].
Sputum eosinophilia is useful for selecting patients that are likely to benefit from an
increase in corticosteroid treatment and is likely to have a useful role in making
treatment decisions in moderate to severe asthmatics. However, collection and
processing of induced sputum samples is time consuming, and requires on-site
laboratory facilities that can process samples within the required time frame. Also,
although the technique is safe, it does induce bronchoconstriction in 10-20% of
asthmatic patients and coughing, and therefore may not be popular with patients.
Therefore, availability of resources and patient acceptability are likely to be the
factors that limit routine use of induced sputum.
INDIRECT MEASURES OF AIRWAY INFLAMMATION
In addition to RHML, exhaled gases, breath condensate and induced sputum cell
counts, there are measures of airway hyper-reactivity and patchiness of ventilation
that can provide information on the degree of severity of asthma
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Airway hyper-responsiveness is recognised as a key feature of asthma which
correlates with symptoms, severity of disease [129]. It is usually assessed by giving
incremental doses of methacholine or histamine and determining the concentration
required to cause a fall in FEV1 of >20%. Airway hyper-responsiveness appears to
be closely associated with airway inflammation [130, 131]. However the suppression
of symptoms and airway inflammation following treatment with inhaled
corticosteroids does not necessarily lead to resolution of bronchial hyper-
responsiveness [132]. Although bronchial hyper-responsiveness can provide some
indirect evidence of the state of airway inflammation in asthma, it may also be
regarded as an additional component of the assessment of disease activity.
Ventilation heterogeneity is described as a feature of asthma in association with
bronchial hyper-responsiveness and airway inflammation. The reasons for ventilation
heterogeneity in asthma are proposed to be a result of airway wall thickening and
mucous secretion due to inflammation. This is often variable throughout the lungs in
asthma reflecting the lack of uniformity in asthmatic airway inflammation [133],
Measurement of ventilation heterogeneity using multiple breath washout tests of inert
gases such as SF6 or nitrogen could provide an indirect assessment of airway
inflammation, although it is impossible to determine whether areas are poorly
ventilated due to mucosal inflammation, transient bronchoconstriction, or airway
remodelling. Heterogeneity could also theoretically magnify the degree of airway
obstruction during airway challenge testing due to higher concentration of the inhaled
broncho-constrictor in well ventilated areas of the lung, rather than areas that are
already constricted [134]. In fact, there appears to be a clearer relationship between
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ventilation heterogeneity and airway hyper-responsiveness, rather than airway
inflammation [measured by exhaled NO; [135].
Although airway hyper-responsiveness and ventilation heterogeneity are associated
with airway inflammation, discordance in changes of these parameters in response to
treatment means that they should be regarded as measures of asthma disease activity
that are complementary to measures of airway inflammation, but cannot be used to
accurately assess inflammation. They may however provide an alternative target for
treatment of asthma.
SUMMARY
There is a clear need for markers of airway inflammation in asthma and numerous
candidates have been proposed. However, judging the clinical utility of a given
marker is hampered by the lack of a gold standard measure of AI, which can be used
for comparison purposes. Bronchoscopy and bronchial washings, lavage, or biopsy is
not feasible on large numbers of patients, and although it provides direct access to the
airways there is no validated bronchoscopic measure for assessing AI in asthma. The
markers that are studied in this thesis have been reviewed in this chapter all have their
advantages and disadvantages, which are summarized in Table 2.
Widely investigated markers such as induced sputum differential eosinophil counts
and exhaled NO appear to be the most promising candidates at present. However
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sputum induction may not always be successful or acceptable with patients and lack
of resources outside of a large teaching hospital setting may limit its widespread
application. Exhaled NO is a simpler measurement to make, but it may be overly
sensitive to steroids making it less useful for monitoring AI in the majority of
asthmatic patients that are established on inhaled steroids. The current data for
exhaled CO is limited due to differences in techniques between studies. Breath
condensate is an appealing method to non-invasively study substances in airway
lining fluid, although none have been clinically validated due to problems with
standardisation and reproducibility of measurements. While most attention has
focused on cellular, biochemical and molecular markers, it is possible that
fundamental changes occurring as a result of AI may have been overlooked, such as
altered respiratory heat loss. The studies that follow are based on the following
hypotheses:
1. RHML will be altered in asthma in association with other markers of
airway inflammation.























































































































































































































































The work reported in this thesis was designed to compare contrasting biophysical,
biochemical and cellular approaches for estimating airway inflammation in asthma in
a single research centre. The markers investigated are:
1. Respiratory Heat and Moisture Loss
2. Exhaled Nitric Oxide
3. Exhaled Carbon Monoxide
4. EBCpH
5. EBC nitrite
6. Induced sputum differential inflammatory cell counts
In particular the characteristics of RHML, which is proposed as a novel marker of
airway inflammation, are subject to detailed study in stable and acute asthma. A
series of cross-sectional and longitudinal studies were undertaken to address the
following key research questions:
1. Are there cross-sectional differences in markers in stable asthma, acute
asthma and control groups?
2. How do these different methods of assessing airway inflammation relate to
one another?
3. How do these markers change as an exacerbation of asthma resolves?
4. How reproducible are these measurements over time in individuals?
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1. Cross-sectional Study of Respiratory Heat and Moisture Loss and Other
Markers of Airway Inflammation in Stable Asthma and Acute
Exacerbations
The aim of this study was to determine whether RHML and other markers are altered
in asthma in association with airway inflammation. RHML measurements in stable
asthmatics, patients with an acute exacerbation of asthma, and control subjects were
made in a cross-sectional comparison. In the asthmatic groups, parallel measurements
of exhaled NO, exhaled CO, EBC pH, EBC NO2" and sputum differential
inflammatory cell percentages were made to examine how these markers relate to
RHML and each other. It was hypothesized that an increase in airway mucosal blood
flow associated with AI in asthmatics would lead to a detectable change in RHML.
2. Longitudinal Study of Respiratory Heat and Moisture Loss and Other
Inflammatory Markers during the Resolution of an Exacerbation of
Asthma
The behaviour of RHML, the exhaled gases, NO and CO, and breath condensate pH
and nitrite are studied in individuals recovering from an acute exacerbation of asthma.
Measurements were made on day 1 of their exacerbation (within 24 hours of
presentation) and between days 3-5 and days 7-9 following treatment as their
exacerbation resolved. The aim was to evaluate the utility of these markers at a time
when one would expect intense airway inflammation to be present. Examining
longitudinal changes in these markers at this time demonstrates the kinetics of change
in these markers as an exacerbation resolves.
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3. Repeatability ofRHML and Other Markers ofAirway Inflammation
The day-to-day repeatability of RHML and the other inflammatory markers was
studied. RHML, Exhaled NO, and EBC pH and nitrite are measured in patients with
clinically stable asthma on two different days within a one week period. This has
great importance in helping to resolve whether alterations in inflammatory markers in




MEASUREMENT OF RESPIRATORY HEAT LOSS
Measurement of respiratory heat loss is not as straight forward as it may seem. To
assess total respiratory heat transfer, both convective and evaporative heat losses must
be measured. Furthermore, as the majority of heat transfer occurs in the upper airway
in resting conditions, the inspirate conditions must be altered to engage the
conducting airways in respiratory heat exchange. This can be done by increasing
minute ventilation and/or lowering the temperature of the inspired air. To allow
comparison between measurements the ventilatory pattern and the inspirate conditions
need to be controlled between tests. In the work presented in this thesis a purpose
built device that incorporates temperature and humidity measurement of inspirate and
expirate, and allows precise control over inspiratory conditions and ventilatory pattern
is used. This allows calculation of total convective and evaporative heat losses which
we have termed Respiratory Heat and Moisture Loss (RHML). The apparatus was
developed by Dr J. McCafferty as part of a separate research project [130],
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Equipment
The equipment consists of an air conditioning unit that produces a cool dry inspirate
of known temperature and humidity at a rate of up to 1.5 L/ s (figure 4). The subject
inhales from the conditioned airstream via a flow-past arrangement (T-Tube; see Fig.
3). Multiple temperature and humidity sensors are located in the inspiratory and
expiratory limbs of the apparatus to allow accurate measurement of the heat energy
content of the inspirate and the expirate. Temperature sensors used are K-type
thermocouples (chromel-alumel bead type), with a 90% response time of 50 ms.
They were calibrated against a mercury standard prior to testing. Humidity sensors
are of thermoset polymer capacitance construction (model HIH-3602-A, Honeywell,
USA) supplied factory calibrated giving relative humidity with an accuracy of ± 2%
and an estimated 95% response time of 5 seconds.
Figure 4. Equipmentfor measuring RHML : • Temperature sensor; aHumidity
sensor; ° End-tidal CO2 samplingport.
Audiovisual ventilation
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On exhalation expired breath will immediately cool and as expired air is often near
saturation with water, condensation will occur. The temperature sensors used were
rapidly adapting and were therefore able to accurately measure expired breath
temperature before significant cooling occurred and to track intra-breath changes in
air temperature. However, the humidity sensors have a much slower response time of
5s and therefore would not be able to accurately assess rapid changes in the humidity.
To address this problem, inspiratory and expiratory air flows were separated using a
valve and a time-weighted average of expired air humidity was measured. We have
calculated that the potential error from time-weighted values is an underestimate of <
5% [136]. There is no reason to expect this error to be systematically different
between patients with asthma and controls. In addition, a valve-isolated section of
heated tubing was attached to the expiratory limb of the apparatus, downstream from
the expired breath temperature thermocouple. The temperature of air inside this tube
was controlled at 35 - 40 °C, which was greater than the temperature of exhaled air
and therefore prevented any condensation occurring. The temperature and humidity
of the expired air inside the heated tubing allowed calculation of the water content of
expired air in each breath. Our moisture measurements have been compared against
the gold standard "freeze out" technique over a range of minute ventilations from
historical data and found to correlate closely [15, 136].
Expiratory air flow was measured using an ultrasonic phase-shift flow meter (model
FR-413, BRDL, Birmingham, UK), which was calibrated for volume (L) using
standard volume syringes (vitalograph, UK). The sensor's 100% response time was
12ms; linearity was < 2% and the residual error due to temperature variation <1% in
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the temperature range 0-40 °C. An audiovisual feedback system was used to guide
subjects to achieve a set tidal volume and respiratory rate. End-tidal CO2 was
monitored and maintained at the normal physiological level throughout testing by
adding small quantities of CO2 where required.
Protocol for Measuring Respiratory Heat and Moisture Loss
The inspired air conditions and respiratory patterns used were chosen to try and
maximise heat exchange in the conducting airways without changing airway calibre.
The temperature and humidity of inspired air were controlled at 10 °C and 50%
relative humidity, giving an absolute humidity of 4.72 g/ m3. The thermal energy
content of air is calculated from these variables using standard formulae and is termed
enthalpy. The enthalpy of the conditioned inspired air was calculated to be 20 J/ L.
During the development of the apparatus for measuring RHML, Dr J McCafferty
demonstrated that RHML appeared to be dependent on tidal volume up to a threshold
value (1.5 L) and thereafter directly proportional to minute ventilation (figure 5, [27]).
Therefore, the audiovisual feedback system was used to guide subjects to achieve a
tidal volume of 1.5 L (expiratory flow rate of 500 ml/ s) and a respiratory rate of ten
breaths per minute, to give a target minute ventilation of 15 L/ min. The thermal
challenge of these conditions over five minutes is not sufficient to affect airway
calibre from pilot data [27].
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Figure 5. Respiratory heat and moisture loss (RHML) plotted against tidal
in healthy control subjects, n=20. RHML is dependant upon tidal volume




Measurements were made using real-time recording of data. All values used were
averages during either inspiration or expiration (figure 6).
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Figure 6. Visual display of raw data used to calculate RHML. During expiration,
measurements are taken from the beginning of the expiratory breath temperature
curve to eliminate equipment dead space (approximately 100 mis). A = inspiration;
B = expiration; RHjnsp = relative humidity of inspirate (%); RHexp = relative
humidity ofexpirate at T4 (%); T2 = temperature of inspirate (°C); T3 = temperature




Calculation ofRespiratory Heat and Moisture Loss
RHML was calculated as the net heat energy loss per unit volume of expired air. The
total heat or energy content of an air-water mixture is given the term enthalpy.
Enthalpy values were calculated using a psychrometric calculator (PsyCalc 98, Linric
Company, Bedford, NH, USA). The enthalpy of the inspirate and expirate are derived
from mean air temperature and water content during inspiration and expiration
respectively. Net enthalpy loss is then calculated as:
h = he -hi
Where: h = net enthalpy loss (J/g dry air), he = enthalpy ofexpirate, and hi =
enthalpy of inspirate.
Total heat energy losses can be calculated by incorporating the mass flow rate into an
equation. The mass flow rate air is the product of air density and flow rate. The
density of a mixture of dry air molecules and water vapour molecules may be
expressed as:
D = [Pf (RdxT)] + /TV (RvxT)J
Where: D = density (kg/m3), Pd = pressure of dry air (Pa), Pv=
pressure ofwater vapour (Pa), Rd = gas constant for dry air [J/(kg x degK)
= 287.0], Ry = gas constant for water vapor [J/(kg x degK) = 461.5], T -
temperature, (degK).
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Total respiratory heat loss is then calculated using the formula:
TRHL = DVx h
Where: TRHL = Total Respiratory Heat Loss (Watts, J/s), D = Density of
air (g/L), V= jlowrate (L/s), h = net enthalpy loss (J/g)
In practice, despite using an audiovisual targeting system, there is some variation
between individuals in expiratory flow rate. Therefore a more useful way of
expressing respiratory heat loss is by heat energy loss per unit volume of expired air.
RHML is calculated using the formula:
RHML =Dxh
Where: RHML = Respiratory Heat andMoisture Loss [Joulesper litre (J/L)],
D = Density ofair/water vapour mixture (g/L), h = net enthalpy loss (J/g).
The data from the temperature and humidity sensors in the RHML equipment allows
accurate measurement of net RHML in Joules per Litre of expired air using the
formulae described.
Application of Existing Equipment to Current Studies
A preliminary study examined the time course of changes in RHML in individuals
while breathing into the RHML apparatus for five minutes. At the inspirate and
ventilatory settings used, RHML decreased over time, possibly due to airway drying
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(figure 7; [137]). Thus, measurements should be taken at the same time point during
each test. In addition, there appeared to be greater RHML in patients with stable
asthma compared with controls in the first two minutes of breathing into the
apparatus. Therefore, in the studies that follow, temperature and humidity
measurements were taken from between 60 and 80 seconds of continuous breathing
into the apparatus. This allows adequate time for the humidity sensors to adjust and
the mean exhaled air temperature to reach a steady state. This is in contrast to a study
by McCafferty et al that reported elevated RHML in asthma once respiratory heat loss
had reached a steady state under similar conditions [136],
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EXHALED NITRIC OXIDE MEASUREMENT
Fractional exhaled NO was measured in single breath using a target expiratory flow
rate of 250 ml/s (FeN02so) with a modified chemiluminescence analyser (LR2000,
Logan Research Limited, Kent, UK). The NO analyser was calibrated daily with
N2/NO calibration gas containing 93 ppb NO (BOC gases, Guilford, UK). A subject
inspires to total lung capacity and with no breath hold, exhales into the sampling tube.
Nasal clips were worn and a visual feedback system was used to maintain a mouth
pressure of 5 cmFLO, sufficient to keep the soft palate closed and prevent nasal
contamination [34], The exhalation tube had a resistor inserted for which a target
mouth pressure of 5 cmFLO was equivalent to an expiratory flow rate of 250 ml/s.
This flow rate was selected as it was more comfortable than the ATS recommended
flow rate of 50 ml/s for subjects with acute or severe asthma, who cannot tolerate very
slow exhalation. There is a literature using an exhalation flow rate of 250 ml/s and
normal ranges in patients with asthma and healthy controls have been widely reported
(see Table 1, Chapter 1).
To measure exhaled NO concentration, expired air was drawn from a sampling tube at
a standard rate of 4 ml/s. NO measurements were taken from the plateau phase at the
end of expiration, in accordance with joint ATS/ ERS guidelines [33]. NO values
were recorded as an average of three measurements. The 95% confidence interval of
for repeat measurements in the same individual was determined by paired
measurements in 32 subjects and was 3.3 ppb.
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EXHALED CARBON MONOXIDE MEASUREMENT
Exhaled CO was measured by an electrochemical CO sensor, sensitive to CO from
0 to 500 ppm by volume, adapted for online recording of CO concentrations and
integrated with the chemiluminescence analyser (LR2000, Logan Research,
Rochester, UK) to control exhalation parameters. The CO sensor was calibrated daily
using 50 ppm CO calibration gas. End-tidal CO (ETCO) levels were taken as an
average from 3 exhalation manoeuvres with a target expiratory flow rate of 250ml/s,
controlled using visual feedback as described above.
EXHALED BREATH CONDENSATE COLLECTION AND ASSAYS
Breath condensate was collected on a commercial breath condenser (EcoScreen,
Jaeger, Germany). Subjects were asked to breathe through a non-rebreathing two-way
valve for 5 minutes. Nose-clips were worn during the collection. The yield of breath
condensate was approximately 1-2 mis. Samples were collected in interchangeable
sampling tubes (one per sample). All sampling tubes were disinfected for 30 minutes
using 1% potassium monopersulphate solution (Virkon, Antec International Ltd, UK),
rinsed for 2 hours by flushing with tap water, then rinsed with ultrapure water (ELGA
Labwater, UK) and air dried prior to use. After collection and pH recording, samples
were stored in polypropylene containers at -80 °C and analysed within 2 weeks to
minimise contamination and problems of instability.
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The pH of the EBC was measured immediately after collection (without deaeration)
using a calibrated pH meter incorporating an ISFET sensor with temperature
compensation (model KS723, Camlab, Cambridge, UK) that has an accuracy of ±0.1
pH. A two-point pH calibration was performed before each breath condensate pH
measurement.
The nitrite concentration in EBC samples was determined by a colorimetric assay
based on the Griess reaction [90] in which triplicates of 100 pi EBC were reacted with
25 pi Griess reagent and measured at absorbance of 570 nm with a microplate reader
(MR 710, Dynatec). This assay has been previously validated [37], Assay sensitivity
was 0.5 pmol/1.
INDUCED SPUTUM COLLECTION AND ANALYSIS
Sputum was induced using incremental concentrations of 3, 4 and 5% hypertonic
saline each delivered over 4 minutes, via an ultrasonic nebuliser (DeVilbiss Ultraneb
99; DeVilbiss Healthcare, Somerset, PA, USA), set at an output of approximately 2.4
ml per minute. Subjects were pre-treated with 200 meg of inhaled salbutamol via a
metered dose inhaler, or salbutamol 2.5 mg via a nebuliser. FEVi was closely
monitored throughout the test and the procedure was abandoned if the FEVi
decreased by > 20%. Subjects were instructed to rinse mouth with water and blow
nose prior to expectorating sputum to minimise contamination with saliva or post
nasal drip.
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Sputum processing was performed using the methods previously described by Pavord
et al [138]. Sputum plugs were separated from the whole sputum sample using
forceps to minimise salivary contamination. The plugs were weighed and four times
the selected sputum volume of 0.1 % dithiothreitol solution was added. The sample
was vortexed for 15 s and then gently mixed for 15 minutes. An equal volume of
phosphate buffered saline was added to the sample. The sample was then filtered
through 53 pm gauze (Lockertex; Warrington, England). The filtered sample was
then centrifuged at 1200 rpm for 10 minutes. The cell free supernatant was removed
and stored for later analysis. The cell pellet was re-suspended in phosphate buffered
saline and cytospins slides were prepared. A haematoxylin and eosin stain was used
for the cytospin.
Sputum differential cell counts were calculated from manual counting of four hundred
inflammatory cells and expressed as percentages of the total inflammatory cell count.
For quality control sputum samples needed squamous contamination of< 20%. When
inflammatory cells were counted on two separate occasions in twelve sputum samples
from subjects with asthma, the correlation coefficient for differential eosinophil
percentage was r = 0.98, p = < 0.001. The intra-observer 95% confidence interval for
sputum eosinophils was ± 2.46%.
STATISTICAL ANALYSIS
The size of the study groups in the cross-sectional study was based on a realistic
achievable number of patients estimated to allow the detection of a significant
difference between groups. Although there was some pilot data available for
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measurement of RHML, the measurement technique used in the studies that follow
were time weighted and therefore differed significantly from previous measurement
by Dr J. McCafferty (see page 54). As a consequence it was not possible to perform a
formal power calculation as part of the study design. The statistical tests used to
analyse data are described within individual chapters.
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CHAPTER III
CROSS-SECTIONAL DATA COMPARING RHML AND
OTHER MARKERS OF AIRWAY INFLAMMATION
INTRODUCTION
The aim of this study was to determine whether RHML is altered in asthma in
association with airway inflammation and whether it bears any relation to the state of
inflammation in the airways measured by alternative non-invasive methods. RHML
measurements in stable asthmatics, patients with an acute exacerbation of asthma, and
control subjects were made in a cross-sectional comparison. In the asthmatic groups,
parallel measurements of exhaled nitric oxide and CO, breath condensate pH and
nitrite, and sputum eosinophils and were made. We hypothesized that an increase in
airway mucosal blood flow associated with airway inflammation in asthmatics would




Thirty-two patients with stable asthma and 25 patients with acute asthma were
recruited to have parallel measurements of RHML, exhaled NO, exhaled CO, EBC
pH and nitrite, induced sputum cell counts and spirometry. In addition, blood samples
were taken from patients with acute asthma to measure peripheral blood eosinophilia.
For comparison with healthy controls, 18 subjects had RHML and spirometry tested.
To establish control values for exhaled NO, exhaled CO, EBC pH and nitrite, a
further control group had these measurements in addition to spirometry.
Subjects
Stable asthmatics were recruited from a hospital outpatient population. Asthma was
defined according to Global Initiative for Asthma (GINA) Guidelines [2]. Sixteen
patients had severe persistent asthma, 12 had moderate persistent asthma and 4 had
mild persistent asthma. All patients were on regular inhaled corticosteroids (mean
daily dose 833 ±561 micrograms of beclomethasone dipropionate (BDP) or BDP
equivalent), and had not experienced any exacerbations of asthma in the two months
prior to the study. Sixteen of the asthmatic subjects were taking a regular long acting
beta-2 agonist (LABA). Inhaled medications were withheld for 12 hours prior to
testing.
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Patients with acute asthma were recruited from a hospital acute medical assessment
unit, and inflammatory markers were measured within 24 hours of presentation.
Acute asthma was defined as deterioration in symptoms with a concomitant reduction
in peak expiratory flow rate (PEFR) from baseline, warranting treatment with a course
of oral prednisolone therapy. This decision was made by the receiving clinician.
Seventeen patients were admitted to hospital for in-patient treatment. All patients had
their body temperature measured. RHML was only tested when core temperature was
< 37.4 °C. Patients with acute exacerbations were treated according to national
guidelines and therefore received nebulised bronchodilators and oral corticosteroids
[3]. Twenty-two of the patients with acute asthma were taking regular inhaled
corticosteroids prior to their exacerbation.
Healthy controls were recruited from hospital staff. All subjects were non-smokers,
or ex-smokers (stopped > 6 months) with a smoking history of less than 10 pack
years. This study was approved by the local ethics committee and all patients and
control subjects gave written informed consent to take part.
Measurement of Inflammatory Markers
The equipment and protocols for collection and analysis of samples are discussed in
detail in Chapter II. In order to minimise possible confounding effects of the test
procedures, the tests were performed in the following order: 1) RHML measurement;
2) exhaled gas analysis; 3) EBC collection; 4) FEVi; and 5) induced sputum
collection. Not all measurements were possible in each individual. The number of
data recordings collected in each group is detailed in figures 8-10. The main factor
61
that limited RHML data collection was equipment failure, including failure of the air
conditioning unit and damage to the humidity sensors. End tidal CO measurements
were not possible for a period due to a lack of calibration gas. Induced sputum
samples were limited for a number of reasons that included unavailability of the
laboratory processing facility, insufficient or inadequate samples and patient refusal.
Figure 8. Profile ofrecordings made in patients with stable persistent asthma
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Figure 9. Profile of recordings made in patients with an acute exacerbation of
asthma.
Figure 10. Profile ofrecordings made in healthy control subjects.
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Statistical Analysis
Results were analysed using Sigmastat® statistical software (SPSS). For cross-
sectional analysis between groups, a one way analysis of variance (ANOVA) was
used determine whether there were any significant differences between groups and a
Tukey post-test analysis was used to determine which groups were significantly
different. For data that were not normally distributed an ANOVA on Ranks was used
to test for differences between groups, and a Dunn's test was used to identify the
groups that differed significantly from one another. Correlations between RHML and
other inflammatory markers in the asthmatic group were determined using a Pearson
Correlation coefficient. Data that were not normally distributed were log normalised
prior to correlation analysis. Levels of significance were determined as p = < 0.05.
Normally distributed data are expressed as mean ± standard deviation (SD) and non-
normally distributed data are expressed as median (inter-quartile range). For each
marker studies, only those patients with a dataset available were studies as opposed to
an intention-to-protocal analysis.
RESULTS
Study groups were well matched in age, height and BMI (Table 3). Percentage
predicted FEV] was significantly lower in stable asthma (83.5 ± 22.1 %) compared
with controls (101.8 ± 7.5; p = < 0.01) and further reduced in acute asthma (55.1 ±
21.4 %) compared with stable asthma (p = < 0.05; Table 4).
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Age 44.6 ± 14.0 44.9 ± 15.2 41.6 ± 13.1 41.6 ± 13.1
Number of
subjects
32 25 18 25
Sex (F:M) 19:13 17:8 10:8 16:9
Height (m) 1.65 ±0.08 1.65 ±0.06 1.68 ±0.07 1.67 ±0.09
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Respiratory Heat and Moisture Loss
RHML was significantly elevated in patients with stable asthma (98.1 ± 7.3 J/L)
compared with control subjects (91.9 ± 4.5 J/L; p = < 0.01), but not in those with
acute asthma (91.3 ± 5.9 J/L; table 4; figure 11). During RHML measurement, there
was no significant difference between groups in the enthalpy of the inspired air (p =
0.06) or the ventilatory pattern (p = 0.93; table 5). The difference observed in stable
asthma is therefore unlikely to be due to variation in test conditions.
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Table 4. Results ofRHML, FEV/ and other inflammatory markers in study groups.
Values are mean ± standard deviation or median (inter-quartile range).
Acute Asthma Stable Asthma Control
Control
(RHML)
N 25 32 25 18
FEV1 (L) 1.7 ±0.7 2.4 ± 0.9 3.3 ± 0.7 3.5 ±0.8
p = < 0.001 p = < 0.001
FEV1 %
Predicted
55.1 ±21.4 83.5 ±22.1 102.1 ±6.8 101.8 ±7.5




























































p = < 0.05
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Figure 11. RHML in control (n=18), stable asthma (n=23) and acute asthma























Stable Asthma Acute Asthma
Table 5. Minute ventilation and enthalpy of conditioned inspired air in stable
asthma, acute asthma and control groups during RHML testing. There was no
significant difference between the enthalpy of inspired air (p=0.06) and the minute
ventilation (p=0.93) between groups.
Stable Asthma Acute Asthma Controls
n 23 19 18
Enthalpy
Inspirate (J/L)




15.9 ±3.4 16.3 ±3.2 16.1 ±2.3
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Due to technical problems with the air-conditioning system of the RHML apparatus,
measurement of RHML was not possible in 7/ 32 patients in the stable asthma group
and 3/ 25 patients in the acute asthma group. Four patients from all study groups
were unable to follow the breath targeting system which requires a degree of co¬
ordination. Patients must be able to time their tidal breathing with an audio cue, and
expire at a set expiratory flow rate, guided by a visual feedback display.
Subgroup analysis of the stable asthma group revealed that there was no significant
difference in RHML between mild/ moderate persistent asthma and severe asthma
(97.8 vs. 98.3 J/L; p = 0.88). In the stable asthma group, there was no significant
difference in RHML between the 16 subjects who were on a regular LABA and
subjects who were not (98.3 vs. 97.5 J/L; p = 0.81).
Exhaled Gases
Median FENO250 was elevated in stable asthma [17.2 (10.0-28.8) ppb; p < 0.001]
compared with control values [6.0 (4.0-8.5) ppb; figure 12]. In acute asthma
FeN025o showed a trend towards a further increase [22.5 (16.7-31.1) ppb; p = 0.06].
End tidal CO was lower in patients with asthma compared with control subjects
across the study groups (p = < 0.01; figure 13). There was no difference in ETCO
between patients with an acute exacerbation of asthma and patients with stable asthma
(p = 0.16).
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The protocols for exhaled NO and ETCO measurement were easy for study
participants to perform. However, a number of ETCO measurements were not
possible for a period during the study due to calibration gas not being available.
Figure 12. Exhaled NO in control subjects (n=25), stable asthma patients (n=32),























Stable asthma Acute Asthma
69
Figure 13. Exhaled CO in control subjects (n=21), stable asthmapatients (n=30),
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Breath Condensate Markers
EBC pH was significantly lower in stable asthma (6.4 ± 0.3; p = < 0.05) compared
with controls (6.6 ± 0.5; table 4; figure 14). In acute asthma there was a further
decrease in EBC pH (6.1; p = < 0.01) compared with stable asthma. EBC nitrite did
not differ significantly in stable or acute asthma compared with control subjects (p =
0.91; figure 15).
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Figure 14. Exhaled breath condensate pH in control subjects (n = 22), stable
asthma patients (n = 31), and patients with an acute exacerbation of asthma
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Figure 15. Exhaled breath condensate nitrite in control subjects (n=23), stable
asthma patients (n=31), and patients with an acute exacerbation of asthma (n=20).




















Control Stable Asthma Acute Asthma
Induced Sputum Eosinophil Percentage
Sputum collection was successful in 19/ 32 patients with stable asthma and 11/ 25
patients with acute, severe asthma. Induced sputum was the most difficult sample to
collect and the reasons for failure to collect sputum are outlined in figures 8 and 9.
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Sputum eosinophil counts were higher in acute asthma [18.7 % (7.3-31.8)] compared
with stable asthma [6.7 % (3.1-13.5); p = <0.05; Figure 16]. Differential neutrophil,
macrophage and lymphocyte counts were not significantly different in stable and
acute asthma (table 6).
Figure 16. Sputum eosinophil percentage in patients with stable asthma (n=19)




































Eosinophil % 6.7 (3.1 - 13.5) 18.7 (7.3-31.8) p = < 0.05
Neutrophil % 62.0 (33.8 - 79.3) 53.8 (37.8 - 74.6) p = 0.93
Macrophage % 23.0 (14.5 - 38.8) 20.0 (6.4 - 26.9) p = 0.18
Lymphocyte % 1.7 (0.9-2.8) 2.4(1.6-4.2) p = 0.18
Correlations between Markers
There was a close correlation between RHML and |Og10 (sputum eosinophil
percentage) in stable asthma (r = 0.73, p - < 0.001; figure 17) but no correlation with
exhaled NO (r = 0.23), EBC pH (r = -0.09), FEV) (r = -0.21) or percentage predicted
FEVi (r = -0.04). In stable asthma, there were no significant correlations between
other non-invasive markers of airway inflammation measured.
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Sputum Eosinophils (%)
In the context of an acute exacerbation of asthma, sputum eosinophils (%; logio)
correlated inversely with percent predicted FEVi (r = -0.83; p = < 0.01; figure 18).
Other markers had no correlation with FEVi. FeNO250 (logio) correlated with
peripheral blood eosinophils (r = 0.64; p = < 0.01; figure 19). However, there was no
significant correlation between exhaled NO and sputum eosinophils (r = 0.48, p =
0.14). There was a weak positive correlation between exhaled NO and EBC pH (r =
0.46; p= < 0.05).
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Figure 18. Correlation between sputum eosinophil cell percentage andpercentage

























Figure 19. Correlation between exhaledNO andperipheral blood eosinophils in
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In this study a direct comparison was made between multiple markers of airway
inflammation in a stable hospital outpatient asthmatic population, a group of patients
with acute asthma and healthy controls. A significant increase in RHML can be
detected in patients with stable but symptomatic asthma. In these patients, there is a
strong correlation between RHML and sputum eosinophilia, a marker of asthmatic
airway inflammation. This suggests that the elevation of RHML in asthma is due to
increased airway inflammation. However, the signal appears to be absent in acute
asthma, where one might expect abundant airway inflammation to cause a further
increase in RHML. In the patients studied here, lower EBC pH levels, reduced FEVi
and elevated sputum eosinophil percentages suggest that airway inflammation was
indeed further increased in acute asthma. Exhaled NO also had a trend towards
elevated levels during an acute exacerbation. In stable asthma, exhaled NO and EBC
pH were able to distinguish asthmatic populations from controls. Exhaled CO and
EBC nitrite did not appear to be valuable markers in the asthma patients studied.
Respiratory Heat and Moisture Loss
Original measurements of the thermal behaviour of airways in lung disease first
appeared in the Russian literature in the 1970s using apparatus that integrated
temperature changes against volume of exhaled air [139]. Improved apparatus was
later used by Agarkov et al to demonstrate differences in caloric output between
control subjects and several patient groups, including patients with bronchial asthma
[140]. No attempt was made in these early studies to quantify evaporative heat loss.
In the present study we have used cooler inspirate, targeted breathing to increase and
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standardise minute ventilation (to engage the lower airway), and exhaled humidity
measurement to quantify evaporative losses. These differences make direct
comparison of the present results with the previous studies difficult.
In the current study, external factors that may influence respiratory heat loss have
been controlled, as far as is possible in a clinical setting (Table 5). Inspiratory
conditions were well controlled across groups and ventilatory pattern was well
matched during each test. Minor differences in respiratory pattern are corrected by
expressing RHML in J/L of expired air.
Drugs used in treatment of asthma may have conflicting effects on airway mucosal
blood flow, potentially confounding this measurement. Inhaled corticosteroids are
vasoconstrictors, whereas beta-2-agonists are vasodilators. Corticosteroids have been
reported to reduce airway mucosal blood flow following two weeks treatment [24],
This is likely to reflect a reduction in inflammation-related vascularity. The acute
effect of inhaled corticosteroids on bronchial blood flow is reported to be a more
transient vasoconstriction that is maximal at 30 minutes and has disappeared by 90
minutes [141]. In contrast, salbutamol is reported to have a vasodilatory effect on the
airway vasculature that may lead to an increase in respiratory heat loss [142],
Nebulised salbutamol can increase airway mucosal blood flow and breath temperature
gradients in control subjects, although this effect is not apparent in asthmatic patients
who already have a higher baseline ofmucosal blood flow [141, 143],
In the present study, inhaler use was controlled in chronic asthmatics (inhalers were
withheld for 12 hours), but ethical considerations precluded altering therapy in the
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acute asthma group. In the chronic asthma group, 16 patients were taking LABAs and
all were taking inhaled corticosteroids (mean dose 833 ± 561 meg of BDP or
equivalent). Despite the potential confounding effect of these treatments,
significantly raised RHML was found in this group. In addition, there was no
significant difference between patients taking a LABA and those not (98.3 vs 97.5
J/L, p = 0.81). It therefore seems unlikely that LABA exerted an effect on RHML
values.
The possible effect of differences in work of breathing on RHML should be
considered. However, there was no correlation between the severity of asthma
measured by percent-predicted FEV i and RHML. Patients, who have a higher work
of breathing, therefore do not appear to have higher RHML.
The link between RHML and sputum eosinophil percentage is an intriguing and novel
correlation between a biophysical and a cellular marker. Monitoring sputum
eosinophil percentage has been reported to have a positive impact on preventing
asthma exacerbations when compared with conventional assessment of asthma in a
randomised controlled trial [128]. A similar impact has not thus far been
demonstrated with other non-invasive markers of airway inflammation.
RHML did not correlate with FEVi, percent-predicted FEV), exhaled NO, or EBC pH
in stable asthma. Spirometry does not always correlate consistently well with
markers of airway inflammation [47, 144], This is probably because inflammatory
markers provide information on current airway inflammation, whereas spirometry
cannot distinguish between background structural damage or remodelling and present
79
inflammation. Furthermore, the absence of a relationship between FEV] and RHML
in the asthmatic group reduces the possibility of the increase in RHML being an
airway calibre effect.
The paradoxical low RHML value observed in acute asthma has a number of possible
explanations, including drug effects and altered pre-test ventilatory conditions. Drugs
used in treatment of acute asthma may have conflicting effects on airway mucosal
blood flow which have been described earlier. Standard practice in the department in
which this study was based is to treat patients with acute asthma with systemic
corticosteroids and nebulised salbutamol and ipratropium bromide. Ipratropium
bromide has been used in allergic rhinitis for its mucosal drying effect [145], although
it has been reported not to affect the ability of the nose to condition inspired air [146].
In contrast, salbutamol is reported to have a vasodilatory effect on the airway
vasculature that may lead to an increase in respiratory heat loss [142]. Oxygen, which
is stored in a dry form, may also have a dehydrating effect on the airway when
delivered directly without humidification. It was not standard practice at the time of
this study to humidify the high flow oxygen that patients receive on admission.
In acute asthma ventilatory pattern is altered. There is an increase in respiratory rate
[147] and inspiratory flow rate is increased [148]. There may also be greater mouth
breathing due to nasal congestion, which reduces upper airway conditioning of
inspired air [149]. These factors in addition to airway narrowing, allow
unconditioned air to penetrate deeper into the conducting airways, which may affect
airway wall temperature and hydration. Moloney et al have reported lower humidity
in exhaled air from patients with acute asthma compared with control subjects. The
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temperature of exhaled air was not significantly different between groups [150].
Although ventilatory pattern was controlled during our tests, it is possible that an
altered breathing pattern prior to testing had some pre-conditioning effect on airway
mucosa that resulted in lower levels of RHML when compared against a stable
asthmatic with a normal resting ventilatory pattern.
The potential clinical consequences of airway drying in acute asthma are worthwhile
considering. This is likely to lead to thicker mucous secretions and may contribute to
airway constriction. Changes in mucosal osmolality have been proposed as a
mechanism for the bronchoconstriction that occurs in exercise induced asthma (151).
At present humidified oxygen and intravenous fluids are recommended in guidelines
for the management of acute asthma, although there is little evidence to support this
recommendation [3]. A potential area for future research would be to study the
possible benefits of strategies to minimise airway dehydration in acute asthma.
Exhaled Gases
In an earlier study of patients with mild asthma, Kharitonov et al reported that exhaled
NO was elevated in steroid naive asthma, but not in steroid treated asthma [54].
However, the elevated exhaled NO levels seen in our cohort of predominantly
moderate-severe persistent asthmatics, who were all on inhaled corticosteroids is in
keeping with a previous report in a similar group of steroid treated asthmatics with
moderate or severe disease [47]. Exhaled NO appears less useful in distinguishing
acute exacerbations from stable asthma according to the present study. This supports
the findings of an emergency department study by Gill et al that reported exhaled NO
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is a poor predictor of asthma severity in patients with asthma exacerbations [152].
However the design of the present study precluded observations as to the pre-
exacerbation exhaled NO levels in those patients who developed acute severe asthma.
In mild untreated asthma, NO has been reported to correlate well with sputum
eosinophils [58]. However, all patients in our stable asthma group were taking
regular inhaled corticosteroids, and in steroid treated patients the relationship between
NO and sputum eosinophils is much less pronounced [47, 144], These two markers
vary in their response to inhaled steroid treatment [56, 153].
Although our data suggest that exhaled NO may have some utility in monitoring
airway inflammation, it is worth noting that 6/ 25 patients with acute asthma had an
exhaled NO value of less than 15 ppb, which has been used as an effective cut-off
level to predict poor asthma control [67], The wide inter-individual variability
precludes the diagnostic use of exhaled NO in individuals.
Previous reports of exhaled CO in asthma have produced conflicting results [71, 77,
78]. In the current study, there was an unexpected decrease in ETCO in stable asthma
and acute asthma compared with controls. This is in marked contrast to two previous
studies that have reported greatly elevated exhaled CO in patients with asthma
compared with controls [78, 154], However, there were significant differences in the
technique used to measure exhaled CO compared with the current study. Zayasu et al
and Yamaya et al both used a 20s breath-hold followed by rapid exhalation, whereas a
slow exhalation was used with no breath-hold in the current study [78, 154], In
addition, the group of asthma patients that had elevated exhaled CO in the study by
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Zayasu et al were steroid naive whereas all asthmatic patients in the current study
were on regular inhaled steroids. Exhaled CO levels rise by approximately 80%
following a 10 second breath-hold, but are unaffected by exhalation flow rate, which
suggests a predominant alveolar source for exhaled CO [71]. Therefore any signal
from airway CO production may be concealed by alterations in alveolar diffusion of
CO.
It is possible that the ETCO levels in asthmatics were sub-maximal, because although
all measured exhalations were greater than 10 seconds, control subjects were
consistently able to exhale for longer than asthmatic patients (particularly those with
an acute exacerbation of asthma). The absence of an elevation of exhaled CO in
asthma may also be explained by uneven emptying of lung units in those patients with
persistent asthma or exacerbations of asthma. Ventilation heterogeneity assessed
using a nitrogen washout technique is associated with bronchial hyper-reactivity in
asthma [133]. Late emptying ofmore severely affected parts of the lung may lead to a
late rise in exhaled CO that may not have been captured in the current study.
Breath Condensate Markers
Hunt et al originally reported that EBC pH was decreased in acute exacerbations, but
similar to control levels in treated asthma [94], EBC pH has since been reported to be
similar to control values in mild asthma, but decreased in moderate to severe asthma
[95], and the results of the current study would be consistent with that observation.
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EBC pH has previously been reported in one study to correlate with sputum
eosinophils in asthma by Kostikas et al [95]. Important differences in the current
study are that EBC samples were not deaerated prior to testing and the cohort of
asthmatics in our study appear to have had more severe disease.
No significant difference in EBC nitrite levels between the three study groups was
demonstrated. This is in contrast to earlier reports that suggested EBC nitrite is
elevated in asthma [92, 93], It is possible that measurement of nitrate in addition to
nitrite may have led to a detectable difference in NO metabolites in asthmatic breath
[91]. Indeed bronchoalveolar lavage fluid nitrate, but not nitrite is reported to
increase following segmental allergen challenge in asthmatic subjects [155],
However, in support of the current data, a recent study has reported that neither EBC
nitrite alone, or combined nitrite and nitrate are different from controls in asthma [43].
The same study did not demonstrate any additional value in incorporating nitrate
measurement for distinguishing cystic fibrosis breath, which has consistently been
shown to be rich in NO metabolites [37], The discordant results reported are likely to
owe much to the great inter-subject variability in EBC nitrite measurements. This
may be due in part to measurement error as the concentrations of nitrite in many EBC
samples were at the limits of detection for the assay used. Other factors such as
variable dilution of samples [85] and intrinsic subject variability are also important.
The interaction between exhaled NO, EBC pH and EBC nitrite is highly complex.
Although pH was reduced in acute asthma and exhaled NO tended to be high, there
was a weak positive correlation between both markers rather than the negative
correlation that might be expected. This suggests that they do not behave in a
predictable fashion in individuals and raised exhaled NO may not be a result of
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airway acidification as suggested by Hunt et al [94], The present findings are
supported by observations in cystic fibrosis, where exacerbations do not result in
increased liberation of NO despite the presence of high levels of metabolites of NO
and low airway pH [43], Another possible explanation for this relationship between
exhaled NO and EBC pH, is that those patients with a low pH had poorly controlled
asthma and were therefore on high doses of inhaled corticosteroid, which are known
to suppress exhaled NO.
Induced Sputum Differential Eosinophil Percentage
In this study, induced sputum eosinophil percentage was higher in acute asthma
compared with stable asthma. In addition, an inverse correlation between percent
predicted FEVj and sputum eosinophil percentage was observed. This suggests that
in this setting, sputum eosinophil percentage may reflect the severity of an
exacerbation. Other investigators have also reported predominant eosinophilic
inflammation during an exacerbation of asthma [156, 157]. However, sputum from
2/11 patients with an exacerbation of asthma was characterised by low eosinophils
and high neutrophils. Neutrophilic inflammation in asthma exacerbations has been
reported elsewhere [158]. There appears to be heterogeneity in the pattern of
inflammation in an exacerbation of asthma, which is likely to affect response to
treatment.
The group of predominantly moderate-severe persistent asthmatics in the current
study were all receiving inhaled corticosteroids. Despite the high mean dose of
inhaled steroid, the median sputum eosinophil percentage was still elevated [5.9
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(1.23-11.0) %], when compared with reported control values [117, 159], perhaps
indicating potential for better control of airway inflammation. Previous studies have
reported that sputum eosinophilia is associated with poor asthma control and
persistent airflow obstruction in asthma [125, 160]. Furthermore, there are three
randomised controlled trials that demonstrate a reduction in exacerbations of asthma
when a strategy aimed at reducing sputum eosinophils is used as opposed to standard
clinical assessment ofasthma control [96, 127, 128].
Other studies that have examined cohorts of patients with severe persistent asthma,
have reported elevated sputum eosinophils despite high doses of inhaled or oral
corticosteroids [10, 124, 161]. This may reflect poor compliance with treatment or a
relative resistance to steroid treatment. Compliance with steroid treatment has long
been recognised as a problem in asthma management. In another study of patients
with difficult asthma nine out of eighteen patients on oral prednisolone had
undetectable levels of prednisolone in their blood [162]. An alternative explanation
for the high levels of sputum eosinophils observed is a relative resistance to treatment.
When a high dose long-acting steroid injection is given to patients with persistent
asthma symptoms despite high dose inhaled steroid treatment, sputum eosinophil
percentage is reported to decrease [125], However such an approach would also
provide effective treatment for individuals who do not comply with their usual asthma
treatment, which may have influenced the results.
A significant problem with using induced sputum differential cell counts as a clinical
tool may be difficulties with sample procurement on a regulator basis. In centres
where induced sputum is used frequently as a research tool, adequate samples are
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obtained in approximately 80-90 % of cases [116, 127, 163], However the success in
obtaining samples may be significantly less out with large research centres. Sputum
analysis also requires adequate laboratory support and time which may limit its use to
larger centres.
A further problem with induced sputum is that differential inflammatory cell
percentages are most commonly reported. Although this may provide an internal
reference within the sample, there is significant potential for error, particularly where
one particular cell type is present in large numbers. For example, in patients with
acute or chronic asthma, who have an abundance of neutrophils in their sputum,
eosinophil percentage may appear low, although the total number of eosinophils may
still be elevated.
LIMITATIONS OF THIS STUDY
Due to equipment availability, the control group for RHML was different form the
control group for exhaled gases and breath condensate. In addition there was no
control group for induced sputum. A single control group with all markers studied
would have simplified this study, although it is unlikely to have altered the
conclusions, as both control groups had similar demographics.
The inspired air conditions for measurement ofRHML were not statistically different
between groups, although there appears to have been trend towards lower inspired
enthalpy in the control group. However, the numerical difference in enthalpy values
between groups appears small. In addition, lower inspired enthalpy would be
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predicted to lead to higher RHML due to a greater thermal challenge to the airways,
and therefore reduce the difference observed between controls and patients with
asthma.
There were missing datasets for individual inflammatory markers in each group and
therefore data was analysed for the measurements that were available for each
individual rather than an intention-to treat protocol. A further criticism of the
statistical analysis is the analysis of multiple correlations between markers. This
increases the possibility of an incidental correlation being found. A correction factor
should perhaps have been incorporated into the analysis to account for the number of
markers and possible correlations studied.
CONCLUSION
Respiratory Heat and Moisture Loss, a novel biophysical marker ofAI is elevated in a
hospital based outpatient asthmatic population. Furthermore, there is a close
correlation between sputum eosinophil percentage and RHML, suggesting that RHML
is elevated due to increased AI. Breath condensate pH and exhaled NO are also
potentially useful markers in the context of asthmatic airway inflammation. However
in the cross-sectional data presented here, their clinical utility appears to vary.
Whereas exhaled NO can distinguish asthmatic subjects from control subjects, it is
less able to differentiate acute asthma from stable asthma. Conversely, exhaled breath
condensate pH can distinguish subjects with acute asthma from those with stable
asthma, but is less able to discriminate between those with asthma and control
subjects. Finally, in acute asthma, induced sputum eosinophil percentage is elevated
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compared with stable asthma, although sample collection was limited in this study by
a number of different factors.
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CHAPTER IV
LONGITUDINAL CHANGES IN MARKERS OF
AIRWAY INFLAMMATION IN ACUTE ASTHMA
INTRODUCTION
Cross-sectional analysis of RHML and the biochemical markers studied has
demonstrated that they appear to vary in their utility. Exhaled NO, breath condensate
pH and differential sputum eosinophil cell count were the only markers that were able
to distinguish groups of patients with acute asthma from those with stable disease.
There is a relative paucity of data for how these markers behave during an acute
exacerbation of asthma. In the following longitudinal study, changes in inflammatory
markers were observed during the resolution of an acute exacerbation of asthma.
Following longitudinal changes in biomarkers in an individual addresses the problem
of inter-individual variability. It also allows observation of the dynamics of change
for biomarkers during a time when severity of airway inflammation is altering rapidly.
The aim of this study was to determine whether RHML, FeN02so, ETCO, EBC pH,




Eighteen of the 25 patients with acute asthma studied in a cross-sectional study of
non-invasive inflammatory markers (Chapter III) had serial measurements ofRHML,
FeNO250, ETCO, EBC pH, EBC N02", and sputum eosinophil percentage.
Measurements were made on day 1 of their exacerbation (within 24 hours of
presentation) and between days 3-5 and days 7-9 following treatment as their
exacerbation resolved. An exacerbation of asthma was defined as a deterioration in
symptoms with a concomitant reduction in PEFR from baseline levels, that warranted
treatment with oral corticosteroids. To avoid methodological interface between the
tests, they were performed in the following order: 1) RHML; 2) exhaled gas analysis;
3) EBC collection; 4) FEVi and 4) induced sputum collection.
Fifteen of the 18 patients recruited were admitted to hospital for in-patient treatment
of their asthma exacerbation. Patients with acute exacerbations were treated
according to British Thoracic Society (BTS) guidelines and therefore received
nebulised bronchodilators and oral corticosteroids [3].
Not all measurements were possible in all individuals at each visit (fig. 20). The
reasons for incomplete data were very similar to those in the cross-sectional study.
These reasons were randomly distributed in the data-set and therefore should not have
caused any sampling bias in the study. Only complete data-sets for each marker were
subsequently analysed.
Results were analysed using Sigmastat® statistical software. Repeated longitudinal
measurements were analysed using a one way repeated measures analysis of variance
(RM ANOVA) to determine whether significant changes occurred. A Tukey Test was
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then used to determine when a significant change occured. For data that were not
normally distributed, a repeated measures ANOVA on Ranks was used with a post-
test Dunn's pairwise comparison to determine when a significant change occurred.
Levels of significance were determined as p = < 0.05.
Figure 20. Profile of data collectedfront patients with an exacerbation of asthma
that had serial measurements of inflammatory markers on day 1, between days 3-5
and days 7-9, following treatment
RESULTS
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Longitudinal changes in inflammatory markers are shown in table 7. Serial
measurements following treatment of an exacerbation of asthma revealed a significant
increase in FEVj (% predicted) from day 1 (55.7 ± 17.0) to day 3-5 (71.3 ± 16.5; p = <
0.001) and a further increase between day 3-5 and day 7-9 (80.0 ± 18.1; p = < 0.05).
Table 7. Summary of changes in FEVi and inflammatory markers as an
exacerbation of asthma resolves. Figures are mean ± SD, or median (inter-quartile
range).
Day of Asthma Exacerbation
Day 1 Day 3-5 Day 7-9
FEV, (L)
(n = 18)
1.9 ±0.8 2.4 ±0.9 2.7 ±0.9
p = < 0.001 p = 0.10
RHML (J/L)
(n = 10)
89.5 ± 6.3 95.4 ± 4.8 91.0 ± 5.8









p = 0.94 p = < 0.01
ETCO (ppm)
(n = 15)




6.0 ±0.4 6.1 ±0.3 6.6 ±0.3
p = 0.44 p = <0.001
EEC N02 (mmol)
(n = 16)
3.71 ±2.26 5.86 ±2.71 5.72 ±2.34
p = < 0.05 p = 0.87
RHML increased between day 1 (89.5 ± 6.3 J/L) and day 3-5 (95.4 ± 4.8 J/L; p = <
0.05) and then decreased significantly by day 7-9 (91.0 ± 5.8 J/L; p = < 0.05; figure
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21). Inspired air conditions and ventilatory pattern targeting were well matched
between groups (table 8).
Table 8. Comparison ofenthalpy ofconditioned inspired air and minute ventilation
between serialmeasurements ofRHML.
Day of Asthma Exacerbation
Day 1 Day 3-5 Day 7-9
Enthalpy Inspirate 21.6 ± 3.5 20.7 ±3.6 19.7 ± 3.0
p = 0.09
Minute Ventilation 15.8 ±3.3 16.3 ±3.9 15.9 ± 3.7
p = 0.60
Figure 21. Longitudinal changes in RHML in patients with an exacerbation of
asthma on day 1, day 3-5 and day 7-9following treatment (*p - < 0.05).
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Exhaled NO decreased significantly after treatment (p = < 0.001). In contrast with lung
function changes, there was no significant difference between FENO250 on day 1 [22.3
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(13.0 - 31.3) ppb] and day 3-5 [21.2 (9.9 - 34) ppb; p = 0.94], The decrease occurred
between day 3-5 and day 7-9 [15.4 (8.3 - 22.6) ppb; p = < 0.01; figure 22].
Figure 22. Longitudinal changes in exhaledNO in acute asthma and its resolution.
(*p = < 0.001)
A similar pattern was observed with EBC pH. There was no significant change
between day 1 (6.0 ± 0.4) and day 3-5 (6.1 ± 0.3; p = 0.44), but a significant increase
between day 3-5 and day 7-9 (6.6 ± 0.3; p = < 0.001; figure 23).
Figure 23. Longitudinal changes in exhaled breath condensate pH during the
resolution ofan exacerbation ofasthma (*p = < 0.001).
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Complete series ofETCO measurements and EBC nitrite assays were available in 15/18
and 16/18 subjects respectively. There was no significant change in serial
measurements of exhaled CO (p = 0.47; figure 24), but EBC nitrite increased between
day 1 and day 3-5 (p = < 0.05; figure 25). Sputum was not analysed as only 4 subjects
had a complete set of samples from three visits.
Figure 24. Longitudinal changes in exhaled CO during the resolution ofan
exacerbation ofasthma. No significant difference between visits.
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Figure 25. Longitudinal changes in EBC nitrite in an acute exacerbation of
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Respiratory Heat and Moisture Loss
The earlier cross-sectional study demonstrated that RHML is not elevated in acute
asthma (Chapter III). The possible reasons for this include drug effects and airway
dehydration due to the altered ventilatory pattern in acute asthma. This longitudinal
data demonstrates that RHML increases between day 1 and day 3-5 of an
exacerbation of asthma. By the time of the second measurement, FEV i had increased
greatly, and most subjects are likely to have had a near normal respiratory pattern.
This supports the hypothesis that RHML measured in acute asthma may be
suppressed due to external factors at the time of initial presentation, such as an
elevated pre-test respiratory rate and drug-related airway drying effects.
A small decrease in RHML is witnessed between day 3-5 and day 7-9, which in the
presence of relatively stable lung function may reflect reduced airway vascularity due
to a reduction in airway inflammation following treatment with oral corticosteroids.
Furthermore, the decrease in RHML was temporally related to changes in exhaled NO
and EBC pH. Regardless of this, it appears that measurement of RHML in acute
exacerbations of asthma will not be useful due the lack of a signal in this setting. It




Following treatment of acute asthma, an increase in EBC pH and a decrease in
exhaled NO lagged behind improvements in lung function, indicating that worsened
airway inflammation persisted beyond the principal period of bronchoconstriction
(figure 26).
Figure 26. The kinetics of change in inflammatory markers during the resolution
of an exacerbation of asthma (* indicates a significant change from day 1,
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The delayed changes in exhaled NO and EBC pH seen in the longitudinal
exacerbation data are similar to the delay in resolution of sputum eosinophilia
compared with lung function described by Pizzichini et al in acute asthma [157]. This
supports worsened inflammation persisting beyond improvements in spirometry and
indicates the latter is limited in guiding anti-inflammatory treatment.
Exhaled NO has previously been reported to respond very quickly to nebulised
budesonide (in 6 hours) in paediatric exacerbations of asthma [164]. However, this
study appeared to include mild "exacerbations" (i.e. transient symptomatic
worsenings) of asthma. Patients were not treated with systemic corticosteroids and
more severe patients who did need systemic treatment were excluded. Also, inhaled
corticosteroids have a topical effect on airway vasculature that reduces blood flow and
may result in a reduction in exhaled NO [141]. A very early reduction in exhaled NO
may have been missed, as the first measurements were made up to 24 hours after
presentation. Also a small reduction in exhaled NO between day 1 and day 3-5 may
have been disguised by the concomitant changes in airway calibre [52], However it
seems more likely that the delayed fall in exhaled NO reflects persistent underlying
inflammation in exacerbations of asthma. The observation that EBC pH follows the
same pattern and the apparent elevation of RHML above baseline levels at 3-5 days
support this theory.
There was no significant difference in EBC nitrite levels between the three study
groups in the cross-sectional analysis of patients with acute asthma, stable asthma and
control subjects (figure 15). However, in the cohort of acute asthmatics that were
studied longitudinally as their exacerbation resolved, EBC nitrite was lower on day 1
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compared with day 3-5. This result should be treated with caution. There are
possible explanations for why nitrite may be lower in acute asthma. A significant
proportion of the patients with acute asthma were treated with antibiotics in addition
to oral steroid and nebulised bronchodilators. This may have altered normal flora of
bacteria which convert nitrate to nitrite. Nitrate may have been elevated in this study,
but was not measured. In addition a reduction in airway pH favours conversion from
NO2" to NO [94], which may lead to depletion of nitrite levels in samples, although in
the current study, no correlation was found between EBC NO2" and EBC pH or
exhaled NO. There are also other technical factors that may have contributed to
measurement error, including poor sensitivity of the assay used at the low
concentrations of nitrite observed, possible variable dilution of breath condensate
samples and uncertainty as to the site of origin of nitrite collected in breath
condensate. Resolving these issues is a complex process and may be of limited
benefit as if anything it appears to be lower in the acute phase of an asthma
exacerbation, a time whether there should be abundant inflammation present.
CONCLUSION
At present anti-inflammatory treatment in exacerbations of asthma is largely
empirical. Perhaps treatment could be tailored more specifically to patients' needs if
measurements of inflammatory indices were incorporated into management of asthma
exacerbations. In the current study, there was considerable heterogeneity in the
response of each marker during the resolution of an exacerbation of asthma. This
probably reflects variability in the severity of an exacerbation and possibly the nature
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of the underlying inflammation or underlying asthma phenotype. However in
subgroups of patients, breath condensate pH and exhaled NO are potentially useful
markers in monitoring treatment response during acute exacerbations of asthma.
Furthermore, exhaled NO, EBC pH (and RHML) lag behind changes in lung function
as an exacerbation of asthma resolves, raising the possibility that they might provide
information regarding the degree of inflammation present that is complementary to
lung function measurements in assessing treatment response in acute asthma.
102
CHAPTER V
REPRODUCIBILITY OF MARKERS OF AIRWAY
INFLAMMATION
One of the problems with the inflammatory markers studied and other proposed
markers ofAI, is that there is wide inter-individual variability in results. This may be
due to variability in the severity of disease, or variability in the measurement
techniques. In order to validate inflammatory markers and to interpret changes within
individuals, it is important to have some understanding of the reproducibility of these
measurements. The aim of the following study was to investigate the day-to-day
repeatability ofRHML and other inflammatory markers in individuals.
METHODS
The day-to-day repeatability of RHML, exhaled NO, breath condensate pH and EBC
nitrite was assessed in eight stable asthmatics, who had two measurements on two
separate days within a one week period at a time when their disease was clinically
stable. FEVi was also recorded on each visit. The patients had a mean age of 42.1 ±
13.9; female: male ratio, 6:2. All patients were taking a regular inhaled corticosteroid
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and 5/ 8 were taking a regular LABA. All were non-smokers. Inhaled medications
were withheld for 12 hours prior to testing. The measurements were taken in the
following order: RHML; Exhaled NO; EBC collection; and FEV], For assessment of
inter-day variability, measurements were taken at the same time of day on each visit.
In this study the repeatability of sputum eosinophils was not assessed (due to
difficulties in previous studies with sample procurement) and it was not possible to
measure exhaled CO (calibration gas not available at the time of the study).
The day-to-day repeatability of RHML was also assessed in nine healthy controls
recruited from a hospital staff. Each subject had two measurements on different days
within a one week period. In addition 12 subjects had back-to-back measurements of
RHML, 10 minutes apart.
The repeatability of inflammatory markers was assessed by calculating the
measurement error (intra-subject standard deviation) for repeated measurements,
using methods described by Bland and Altman [164]. Confidence intervals for
measurements were calculated as ± 1.96 x measurement error. The correlation
coefficient of repeated measurements was calculated using a Pearson test. All data
are expressed as mean ± SD. Inspired air conditions for RHML measurement were
compared using a paired t-test.
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RESULTS
Respiratory Heat and Moisture Loss
Mean values of RHML, FeNC>25o, EBC pH and EBC nitrite on visit 1 and visit 2 are
detailed in table 9. The day-to-day repeatability of these inflammatory markers is
presented as Bland and Altman plots in figure 27. Repeat measurements ofRHML in
eight stable asthmatics demonstrated a day-to-day measurement error for this test of
2.3 J/L, giving a 95% confidence interval of± 4.6 J/L. In healthy controls, day-to-day
repeat measurements of RHML had a measurement error of ± 1.6 J/L, giving a 95%
confidence interval of ± 3.1 J/L. Overall, the correlation coefficient between day-to¬
day repeat measurements of RHML was r = 0.91; p = < 0.001 (Table 9; Figure 28).
There was a tendency for greater variability in repeated measurements, as RHML
increased (figure 27). For all subjects, inspired air enthalpy was similar on visit 1
(22.9 ± 1.3) and visit 2 (22.7 ± 1.0 J/L; p = 0.70), as was the minute ventilation (15.1
± 1.8 vs 15.2 ± 2.2 L/min; p = 0.45). Back-to-back measurements of RHML had a
95% confidence interval of ± 3.0 J/L, and a correlation coefficient of r = 0.82 (p = <
0.01; figure 29).
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Table 9. Day-to-day reproducibility of RHML, FEN02so, EBC pH and N02~
measurements in patients with stable asthma. Measurement values are mean ± SD.




FEV, 2.43 ± 0.54 2.40 ± 0.62 0.98 <0.001
RHML
Asthma 96.6 ±3.5 97.7 ±3.3
0.91 <0.001
Control 88.0 ± 5.1 87.8 ±6.2
FeN025o 34.3 ± 26.4 32.5 ± 22.4 0.96 <0.001
EBC pH 6.4 ± 0.3 6.2 ± 0.3 - 0.21




































































































































Figure 28. Measurement ofRHML in patients with stable asthma (O) and healthy
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Figure 29. Bland and Altman plots of back-to-back measurements of RHML in
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Biochemical Markers
For day-to-day repeat measurements of FENO250, the measurement error was 4.8 ppb,
giving a 95% confidence interval of ± 9.5 ppb. The correlation co-efficient between
the two measurements was r = 0.96 (p = < 0.001; Table 9). Repeated breath
condensate pH measurements had a 95% confidence interval of ± 0.27. The
correlation coefficient between repeated measurements was not significant (p = 0.21).
Six paired EBC nitrite samples from different days within a one week period were
analysed. The other samples did not have matching pairs due to one missing sample
and one inadequate sample. The 95% confidence interval for repeated measurements
was ± 2.26, and there was a significant correlation in EBC nitrite between visits (r =
0.96; p = <0.01).
DISCUSSION
Respiratory Heat and Moisture Loss is a reproducible test in patients with stable
asthma and control subjects. Exhaled NO and breath condensate nitrite were also
reproducible in patients with stable asthma (although EBC nitrite was examined in
only six subjects). In contrast, breath condensate pH was poorly reproducible in this
cohort of stable asthmatics.
Respiratory Heat and Moisture Loss
RHML appeared to be reproducible and the changes that were observed in the
exacerbation study were greater than the error margin of the test. From the current
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data, a change in RHML of genuine significance is 4.6 J or a 5% difference between
measurements. The variability in RHML may be due to problems with the
measurement technique, which could be refined. Previous data has demonstrated that
RHML is time sensitive and decreases during a five minute test, with the ventilatory
settings used in this series of test (figure 7, Chapter II). To standardise measurements,
a time-weighted measurement is used, in addition to controlled inspirate conditions
and respiratory pattern. However the timing of measurements remains a potential
source of measurement error. In addition, the pre-test respiratory pattern was not
rigorously assessed. Greater mouth breathing or an altered respiratory rate or tidal
volume before the test may affect measurements, as previously suggested in
exacerbations of asthma.
There appears to be greater day-to-day variability as RHML increases. This is of
particular relevance to the asthmatic patients studied, who had higher values of
RHML. It is difficult to separate intrinsic disease variability from variability due to
the measurement technique or equipment. However day-to-day repeatability appeared
to be better in control subjects, who had a wide scatter of RHML recordings,
suggesting that intrinsic variability in the state of the airway contributed partly to the
increased variability in asthma.
The effect of medications (ICS, LABAs) was controlled to some extent, as inhaled
medications were withheld for 12 hours prior to testing. It is unlikely that
withholding these drugs for a short period of time had any effect on asthma control.
FEV i was monitored on each visit and was similar.
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Biochemical Markers
Measurement of exhaled NO is highly variable between individuals (figure 12,
Chapter III). It is a sensitive technique and one of its problems is that it may be
affected by many different factors, including atopy and viral respiratory tract
infections [46, 48, 166]. Nevertheless, the day-to-day repeat measurements of
exhaled NO in this study were reproducible. Kharitonov et al have previously
reported that exhaled NO is a reproducible and also free from diurnal variation [41].
However, the longitudinal changes in median exhaled NO during the resolution of an
exacerbation (Figure 22, Chapter IV) were within the 95% confidence interval for
day-to-day repeated measurements in stable asthmatics. It is possible that
determining individual 'normal' ranges could enhance the clinical utility of this test,
or that a subgroup of patients with asthma could be identified, in whom the test is
sensitive to changes in AI.
Breath condensate pH has poor day-to-day intra-subject repeatability. As with other
markers of inflammation studied, it is difficult to know if variability in EBC stems
from the measurement method or the assay technique. Leung et al have reported that
EBC pH in non-deaerated samples was reproducible on consecutive days, although
there was no correlation between samples collected through different devices [167],
This suggests that sampling technique may be relevant in explaining the variability in
EBC analytes. However, in the current study, the method of collection of EBC was
standardised (Chapter II), and in contrast to EBC pH, nitrite appeared to be
reproducible in the 6 subjects with paired samples.
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De-aeration (removal of C02) of EBC samples is proposed as a method of stabilising
pH levels in breath condensate. Vaughn et al have reported that de-aerated EBC pH is
a stable and reproducible assay in healthy control subjects [100]. Alternatively,
standardisation of samples to a pre-determined C02 level is reported by Kullman et al
to greatly enhance the reproducibility of EBC pH measurements [168]. However de-
aeration increases the complexity of what is otherwise a simple measurement. In the
current study, EBC samples were not de-aerated prior to pH measurement. This
approach is supported by a previous study in the same lab, where Tate et al reported
that EBC pH without de-aeration was reproducible in CF patients with stable disease
and controls [169],
The inter-day reproducibility of RHML and exhaled NO in patients with stable
asthma are described in this study. The fluctuations in RHML observed in the
resolution of an exacerbation of asthma (Chapter IV), are likely to be significant as
the magnitude of change is greater than the day-to-day repeatability. However,
changes in exhaled NO during the resolution of an exacerbation of asthma are within
the 95% confidence intervals for day-to-day measurements in stable asthma. Serial
EBC pH measurement is less reproducible. This makes interpretation of small
changes in exhaled NO and EBC pH difficult and raises questions over whether these




Monitoring inflammation in asthma presents a number of challenges. A marker of
inflammation must provide clinically useful information about the complex airway
inflammation that causes asthma. As the airways are not directly accessible, there
also needs to be reasonable confidence that non-invasive samples taken reflect disease
processes in the airway mucosa. The inflammatory markers that we have examined in
this manuscript vary considerably in their clinical utility.
Respiratory heat and moisture loss is elevated in stable persistent asthma and is
reproducible in back-to-back measurements and in day-day measurements.
Furthermore a correlation between RHML and sputum eosinophil percentage, and the
elevated values at day 3-5 of an exacerbation, supports the hypothesis that the altered
RHML in asthma is due to the presence of airway inflammation. However, it is not
elevated at the onset of exacerbations of asthma. There are plausible explanations for
what appears in the first instance to be a surprising result. In acute asthma, an altered
ventilatory pattern, and the airway drying regimens that are part of the management of
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exacerbations asthma are likely to affect the condition of airway mucosa in proximal
conducting airways.
The attraction of RHML as a marker of airway inflammation is that is non-invasive,
inexpensive, a global rather than a regional airway sample, and it measures
inflammation non-specifically rather than relying on a specific inflammatory pathway.
We believe that this technique is better suited to measure changes in heat exchange in
the conducting airways compared with previous attempts because of the augmented
ventilatory pattern and the cool inspirate used, which allows unconditioned air to
engage the sub-glottic airway. The most significant challenge of this technique is that
it is sensitive to extrinsic changes in the temperature and water content of inspired air.
In addition, accurate measurement of real-time humidity changes presents a technical
challenge. In this study, a time-weighted average of humidity changes was used to
track inter-breath changes in humidity, due to the slow response time of the miniature
humidity sensors that are commercially available. The technique for measuring
RHML could be simplified by using rapidly adapting "chilled mirror" type humidity
sensors. This would allow real-time tracking of changes in humidity. RHML
measurements could then be made in a single breath test which would reduce the
possibility of airway drying affecting the results. Improvements such as this to the
equipment could reduce the error margin of RHML measurement, but are unlikely to
alter the general conclusions from the cross-sectional and longitudinal exacerbation
studies reported here.
Exhaled nitric oxide can distinguish asthmatic from non-asthmatic populations in
contrast to the other exhaled gas examined, carbon monoxide, which was not elevated
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in asthma. Furthermore changes in exhaled NO during exacerbations of asthma were
able to track changes in the degree of inflammation as an exacerbation resolved. This
may be a useful observation particularly as changes in exhaled NO were dissociated
from changes in FEVi, suggesting that airway inflammation persisted beyond the
principal period of bronchoconstriction. Exhaled NO is of more limited use in
asthmatic patients taking regular inhaled corticosteroids [47], However, these data
demonstrate that it remains elevated in moderate to severe persistent asthma, and
during exacerbations of asthma where airway inflammation is uncontrolled. A
distinct advantage of exhaled NO is that the measurement technique has been
standardised. In addition there are commercially available handheld exhaled NO
devices that may facilitate home monitoring of exhaled NO. Day-to-day
measurements of exhaled NO were reproducible, but the fluctuations in this test
between days was enough to cast doubt on whether the change in exhaled NO
observed during the resolution of an exacerbation of asthma were clinically
significant.
Exhaled CO measurements were also able to distinguish asthmatic patients from
controls, although surprisingly end-tidal CO was lower in patients with asthma.
Elevated levels of exhaled CO following a breath-hold and a continuous slow rise in
exhaled CO during exhalation, suggest that a significant amount of it is from an
alveolar source [71]. Therefore the signal from any change in CO released by airway
inflammation may be obscured by high levels of alveolar CO. The reason why
exhaled CO was lower in patients with asthma is unclear, although a shorter duration
of exhalation, resulting in submaximal end-tidal CO is one possible explanation. The
absence of any significant change in exhaled CO during the resolution of an
115
exacerbation of asthma supports our conclusion that exhaled CO measurements do not
reflect changes in airway inflammation.
Exhaled breath condensate provides a non-invasive means of sampling airway lining
fluid. However the samples are very dilute, and possibly variably dilute [85]. In
addition, without intubating a patient it is difficult to avoid contamination from the
upper respiratory tract [35], It is therefore difficult to know what is being measured
and where it is from. Fluctuations in a substance being measured may be due to
variable dilution of the sample, or changes in concentrations of inflammatory markers
in the airway lining fluid. Although exhaled NO is elevated in asthma, its metabolite
nitrite is not elevated in EBC from individuals with asthma. On the other hand,
exhaled breath condensate pH shows some potential as a measure of airway
inflammation in acute asthma. EBC pH is low in acute asthma and rises as an
exacerbation of asthma resolves. The changes in EBC pH have a temporal
relationship with exhaled NO, in contrast with changes in FEV|. However EBC pH
had wide inter-individual variability and the intra-day reproducibility of
measurements was poor. It is possible that the repeatability of EBC pH measurement
could be enhanced by de-aeration or gas standardization ofEBC samples [100],
Induced sputum eosinophil counts are widely reported as useful in assessing airway
inflammation [127], Induced sputum eosinophil percentage can distinguish patients
with acute exacerbations of asthma from patients with stable asthma. In addition,
sputum differential cell counts provide not only a quantitative measurement, but also
information regarding the nature of the inflammation present. However, a significant
disadvantage of induced sputum is the difficulty in obtaining adequate samples. In
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centres which specialise in this measurement, adequate samples are obtained in
approximately 80% of patients [127]. Out with a research setting, this figure may be
less. This may make longitudinal assessment of patients difficult. This technique is
also cumbersome, relies on the availability of adequate histopathological facilities and
samples should be processed in under 2 hours [138]. This may limit the widespread
clinical use of induced sputum cell counts.
All of the inflammatory markers examined in this thesis were highly variable between
individuals in the same study groups, whether in stable asthma or acute asthma. Some
of this will be measurement error due to the equipment or measurement techniques
used. A further factor is that asthmatic airway inflammation is complex and it is
increasingly being recognised that the spectrum of asthma includes some distinct
disease phenotypes. It is possible that the utility of the various inflammatory markers
studied here may become more apparent once there is a better understanding of the
different subgroups of asthma. Further studies are required to understand how these
inflammatory markers behave in particular subgroups of asthma.
To enhance the accuracy of the inflammatory markers proposed in this thesis, further
work is required to refine the measurement techniques. This is particularly true for
RHML and EBC markers. RHML is a novel inflammatory marker and there is scope
to improve upon the measurement technique used in this thesis. For example using
more accurate humidity sensors would allow a shorter test to be performed, making it
less likely that the test itself will alter the airway environment. Further longitudinal
studies are required to assess the clinical utility of these markers of airway
inflammation. Longitudinal changes during the resolution of an exacerbation of
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asthma were examined in the current study. However a phased reduction and
withdrawal of inhaled steroids would be an alternative method of provoking an
increase in airway inflammation.
The data presented in this thesis adds to the current literature that helps to reveal the
clinical utility ofmeasurement of exhaled nitric oxide, exhaled breath condensate pH
and induced sputum differential cell counts in stable and acute asthma. From the
current studies, exhaled CO and EBC nitrite appear to be less useful as markers of
inflammation, as they do not appear to be elevated in stable asthma, or during an
exacerbation. A novel method for measuring respiratory heat and moisture loss has
been described. This may provide an alternative biophysical measure of airway
inflammation, although it is likely to be limited to patients with stable persistent
asthma, and not acute asthma. Non-invasive monitoring of airway inflammation
remains a challenge, but it is possible that some of the inflammatory markers
discussed here will aid physicians in their clinical management of difficult asthma
cases in the future.
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FIGURES
Figure 1: RHML in Joules / L of ventilation in asthmatics and healthy controls.
Figure 2: Counter current method of breath condensate collection.
Figure 3. Summary diagram of the origin of inflammatory biomarkers of asthmatic
airway inflammation in exhaled air and exhaled breath condensate.
Figure 4. Equipment for measuring RHML
Figure 5. Respiratory heat and moisture loss (RHML) vs. tidal volume in healthy
control subjects, n = 20. RHML is dependant upon tidal volume up to a threshold
value of 1.5 L [22],
Figure 6. Visual display of raw data used to calculate RHML.
Figure 7. RHML during 5 minute test in subjects with asthma (n=21) and control
subjects [n= 18; [131]].
Figure 8. Profile of recordings made in patients with stable persistent asthma
Figure 9. Profile of recordings made in patients with an acute exacerbation of asthma.
Figure 10. Profile of recordings made in healthy control subjects.
Figure 11. RHML in control (n = 18), stable asthma (n = 23) and acute asthma (n =
19) study groups (* p = < 0.01).
Figure 12. Exhaled NO in control subjects (n = 25), stable asthma patients (n = 32),
and patients with an acute exacerbation of asthma (n = 25; * p= < 0.01; Dunn's Test).
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Figure 13. Exhaled CO in control subjects (n = 21), stable asthma patients (n = 30),
and patients with an acute exacerbation of asthma (n = 21). p-values represent
comparison between groups using a t-test.
Figure 14. Exhaled breath condensate pH in control subjects (n = 22), stable asthma
patients (n = 31), and patients with an acute exacerbation of asthma (n = 24; # p = <
0.05; * p = <0.01).
Figure 15. Exhaled breath condensate nitrite in control subjects (n = 23), stable
asthma patients (n - 31), and patients with an acute exacerbation of asthma (n = 20).
Figure 16. Sputum eosinophil percentage in patients with stable asthma (n = 19) and
acute exacerbations of asthma (n = 11; # p < 0.05).
Figure 17. Correlation between RHML and sputum eosinophil percentage in stable
asthma.
Figure 18. Correlation between sputum eosinophil cell percentage and percentage
predicted FEV) in acute asthma (Pearson; r — -0.83; p — < 0.01).
Figure 19. Correlation between exhaled NO and peripheral blood eosinophils in acute
asthma. (Pearson; r = 0.64 ; p = < 0.01)
Figure 20. Profile of data collected from patients with an exacerbation of asthma that
had repeat measurements of inflammatory markers on day 1, and between days 3-5
and days 7-9, following treatment.
Figure 21. Longitudinal changes in RHML in patients with an exacerbation of asthma
on day 1, day 3-5 and day 7-9 following treatment (* p = < 0.05).
Figure 22. Longitudinal changes in exhaled NO in acute asthma and its resolution. (*
p = <0.001)
Figure 23. Longitudinal changes in exhaled breath condensate pH during the
resolution of an exacerbation of asthma (* p = < 0.001).
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Figure 24. Longitudinal changes in exhaled CO during the resolution of an
exacerbation of asthma. No significant difference between visits.
Figure 25. Longitudinal changes in EBC nitrite in an acute exacerbation of asthma
(* p = <0.05).
Figure 26. The kinetics of change in inflammatory markers during the resolution of
an exacerbation of asthma (* p = < 0.01).
Figure 27. Bland and Altman plots of day-to-day repeat measurements of RHML*,
Exhaled NO, breath condensate pH and nitrite in individuals with asthma (*and
control subjects^.
Figure 28. Measurement of RHML in patients with stable asthma and healthy
controls in two tests within a one week period (r = 0.91; p = < 0.001).
Figure 29. Bland and Altman plots of back-to-back measurements or RHML in
healthy controls (n = 12).
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LIST OF ABBREVIATIONS
AI Airway inflammation FEVi Forced expiratory
BAL Broncho-alveolar volume in one second
lavage FVC Forced vital capacity
BDP Beclomethasone HO-1 Heme-oxygenase-1
diproprionate ICS Inhaled corticosteroid
CF Cystic fibrosis IFN-y Interferon gamma
CO Carbon monoxide LABA Long acting beta-2
C02 Carbon dioxide agonist
COPD Chronic obstructive NO Nitric oxide
pulmonary disease N02" Nitrite
EBC Exhaled breath NOf Nitrate
condensate PEFR Peak expiratory flow
ETCO End-tidal CO rate
FENO50 Fractional exhaled nitric RHML Respiratory heat and
oxide at an exhalation moisture loss
rate of 50 ml/s TNF-a Tumour necrosis factor
FeN025o Fractional exhaled nitric alpha
oxide at an exhalation
rate of 250 ml/s
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ABSTRACT: Increased mucosal vascularity is a hallmark of airway inflammation in asthma. It was
hypothesised that this would lead to a detectable increase in respiratory heat and moisture loss
(RHML), which would reflect the degree of airway inflammation present.
A total of 23 subjects with asthma and 18 healthy controls had RHML measured in a cross-
sectional study. The measurements were made using a device that combines temperature and
humidity measurement during inspiration and expiration and allows precise control over inspirate
conditions and ventilatory pattern. The subjects with asthma underwent parallel measurements of
exhaled nitric oxide, sputum eosinophil percentage and exhaled breath condensate pH.
Mean± sd RHML was elevated in patients with asthma (98.1 ± 7.3 J L'1) compared with control
subjects (91.9±4.5 J-L'1). RHML measurement in asthma correlated with sputum eosinophil
percentage.
This novel correlation between thermal and cellular measurements in asthma suggests that
both of these noninvasive indices are sensitive to the degree of underlying chronic airway
inflammation.
KEYWORDS: Airway Inflammation, asthma, exhaled breath condensate pH, exhaled nitric oxide,
respiratory heat loss, sputum eosinophils
Airway inflammation in asthma is charac¬terised by increased mucosal vascularity.This has been demonstr ted in bronchial
biopsies [1-3J and using high-magnification
videobronchoscopy (1 j. Airway mucosal blood
flow, estimated using a soluble gas uptake
method, is also reported to be elevated in patients
with asthma compared with control subjects [5j.
It was hypothesised that an increase in airway
mucosal blood flow associated with airway
inflammation in asthmatics would lead to a
detectable increase in respiratory heat and
moisture loss (RHML).
During normal respiration, a counter-current
mechanism for respiratory heat transfer operates
(6j. As air is inspired, it is heated and humidified,
resulting in cooling and drying of the airway
mucosa. By the time air reaches the alveoli it is at
body temperature and fully saturated with water
vapour. During expiration, a variable fraction of
the available heat energy is regained by the
mucosa as air exits the lung, and the remainder is
exhaled, resulting in net heat loss. Conditioning
of inspired air is dependent on a source of heat
and water. This comes from airway mucosal
blood flow.
There is some evidence to suggest that respira¬
tory heat flux may indeed be altered in asthma,
and measurement of respiratory heat loss lias
been proposed as a marker of lung disease [7, 8j.
Paredi et al. [9j reported a faster rise in breath
temperature during expiration in asthmatics
compared with controls. However, in this study
measurements were made with subjects breath¬
ing ambient room air and evaporative heat loss
was not assessed. This is relevant because in
resting conditions, the majority of heat exchange
takes place in the upper airway and evaporative
heat loss is a major component of total heat loss
from the respiratory tract [10]. In intubated
patients, measurements of tracheal temperature
do not accurately predict total respirator}' heat
losses, but measurement of absolute humidity
appears to be a better predictor [11 J.
The conducting airways become progressively
more involved in respiratory heat exchange as
either the inspired air temperature is lowered or
the minute ventilation is augmented [12]. A
potential hazard of these manoeuvres is that they
may a1st) alter the airway environment, by
changing airway calibre or altering mucosal
blood flow. In fact, the main focus of research
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into respiratory heat exchange in asthma has been the effects of
extreme ventilatory conditions on the airway in the pathogen¬
esis of exercise or cold air-induced asthma [13]. To engage the
subglottic ainvay in heat exchange, with the purpose of
measuring disease activity, conditions should be used that
involve the lower airways in this process without altering their
airway structure or function. In contrast to previous studies,
the present authors thus used an inspirate of conditioned air
with a lower temperature and water content than room air and
moderately elevated minute ventilation. These conditions
create a modest thermal challenge that does not affect airway
calibre, but Is still sufficient to engage the lower airway in heat
exchange [14J.
The aim of the current study was to determine whether RHML
measured under these precisely controlled conditions is
altered in asthma in association with airway inflammation
and whether it bears any relation to the state of inflammation
in the airways measured by alternative noninvasive methods.
RHML measurements in asthmatic and control subjects were
made in a cmss-sectional comparison. In the asthmatic group,
parallel measurements of exhaled nitric oxide (eNO), sputum




A total of 23 subjects with stable persistent asthma and 18
healthy controls were recruited. The subjects in the asthma
group were recruited from respiratory outpatient clinics. They
had had no exacerbations, nor any oral corticosteroid
treatment, for ^2 months prior to the study. Asthma was
defined and classified according to Global Initiative for
Asthma guidelines [15J. Out of the 23 asthmatic subjects, 11
had severe persistent asthma, eight had moderate persistent
asthma and four had mild persistent asthma. Healthy controls
were recruited from among hospital staff. All were non-
smokers or ex-smokers (stopped >6 months ago) with a
smoking history of <10 pack-yrs. All asthmatic subjects were
taking regular inhaled corticosteroids (mean dose 867 + 597 (.ig
beclometasone diproprionate or equivalent). In total, 16 of the
asthmatic subjects were taking a regular long-acting |L-agonist
(LABA). Inhaled medications were withheld for 12 h prior to
testing. The study was approved by the local ethics committee
and all subjects gave written informed consent.
Study design
RHMl. and forced expiratory volume in one second (FEVi;
Vitalograph, Buckingham, UK) were measured in the asthma
and control groups. The asthmatic group underwent parallel
measurements of other inflammatory markers after their
RHML measurement. To minimise interaction between the
measurement techniques, procedures were performed in the
following order during a single visit: RHML measurement,
e>30 measurement, EBC collection, FEVi and induced sputum
collection.
The day-to-day repeatability of RHML measurement was
assessed in nine control subjects and eight stable asthmatics,
who underwent two measurements on two separate days
within a 1-week period.
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RHML apparatus
RHML was measured using a purpose-built device (fig. 1)
incorporating temperature and humidity measurement of
inspirate and expirate and allowing precise control over
inspiratory conditions and ventilatory pattern. Temperature
sensors were K-type thermocouples (chromel-alumel bead
type), with a 90% response time of 50 ms. They were calibrated
against a mercury standard prior to testing. Humidity sensors
were of thermoset polymer capacitance construction (H1H-
3602-A; Honeywell, Morrlstown, NJJ, USA), supplied as factor}'
calibrated, giving relative humidity (RH) with an accuracy of
+ 2% and an estimated 95% response time of 5 s. This respoase
time, which Is the fastest available from practical sensors,
precluded intra-breath measurements, so iaspiratory and
expiratory flow were separated by a valve and RH and breath
temperature were recorded dowastream as time-weigh ted
averages during expiration. It has been calculated that the
potential error from using time-weighted values for humidity
measurement is an underestimate of <5% [16], Expiratory air¬
flow was measured using an ultrasonic phase-shift flow-meter
(FR-413; BRDL, Birmingham, UK), which was calibrated for
volume (at ambient temperature and pressure and saturated
with water vapour) using standard volume syringes
(Vitalograph). The sensor's 100% response time was 12 ms;
linearity was <2% and the residual error due to temperature
variation <1% in the temperature range 0-40 C.
Target iaspiratory air conditioas of 10 C and 50% RH were
created using a purpose built air conditioning device. The
enthalpy of inspired air was therefore - 20J L"1. An audio¬
visual feedback system was used to guide subjects to achieve a
tidal volume of 1.5 L (an expiratory flow rate of 500 mL s"1 and
a respiratory rate of 10 breaths-min"1, to give a target minute
ventilation of 15 L-min"1). This degree of elevated ventilation
and cool inspirate was selected in order to engage the lower
airway in heat exchange. Pilot studies have demonstrated that
the thermal challenge of these conditions Is not sufficient to
affect ainvay calibre in a 5-min test [14]. Validation studies
with this apparatus [16], have shown the calculated moisture
Ventilation
FIGURE 1. Apparatus for measurement of respiratory heat ard moisture loss.
• : temperature sersor; □; moisture sersor; ■: erd-tidal C02 sampling port.
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loss for a range of minute ventilations agrees with published
values using the gold standard-freeze out method (10).
Measurements were made after 1-min breathing into the
apparatus. It was determined from pilot data that this is the
optimum time for detecting alterations in RHML [17], allowing
adequate time for the humidity sensors to adjust and the mean
exhaled air temperature to reach a steady state.
RHML calculation
The total heat or energy content of an air/water mixture is
given the term enthalpy. Enthalpy values were calculated
using a psychrometric calculator (PsyCalc 98; Linric Company,
Bedford, NH, USA). The enthalpy of the inspirateand expi rate
are derived from mean air temperature and RH during
inspiration and expiration respectively. Net enthalpy loss is
then calculated as:
h—ho-hi (1)
Where h—net enthalpy loss (Jg dry air'1), ho—enthalpy of
expirate and In—enthalpy of inspirate.
RHML is then calculated using the following formula:
RHML-Dxh (2)
Where D—density of air/water vapour mixture (g-L*1).
eNO
Fractional exhaled nitric oxide (FeNO) was measured in single
breath using a target expiratory flow rate of 250 mL-s"1
(FeNO2*,) with a modified chemiluminescence analyser
(LR2000; Logan Research Limited, Rochester, UK). The NO
analyser was calibrated daily with N2/NO calibration gas
containing 93 ppb NO (BOC Gases, Guildford, UK). A visual
feedback system was used to maintain a mouth pressure of
>5 mmHg, sufficient to keep the soft palate closed and
prevent nasal contamination. NO measurements were taken
from the plateau phase at the end of expiration, in accordance
with American Thoracic Society/European Respiratory Society
(ERS) guidelines [18]. NO values were recorded as an average
of three measurements. The measurement error in repeat
measurements in the same individual was +1.7 ppb, giving a
95% confidence interval (CI) of +3.3 ppb.
EBC pH
EBC was collected using a purpose-built condenser
(EcoScreen; Jaeger, Wurzburg, Germany). Subjects, wearing a
nose-clip, were asked to breathe through a nonrebreathing
two-way valve into the apparatus for 5 min. Exhaled air was
conducted through a lamellar condenser to an interchangeable
sampling tube (one per sample) situated in a cooling cuff,
cooled to -10 C. Condensate pH was measured immediately
after collection (nondeaerated) using a calibrated pH-meter
incorporating an ion-sensitive field-effect transistor sensor
with temperature compensation (KS723; Camlab, Cambridge,
UK) with an accuracy of +0.1 pH units. The pH-meter
underwent a two-point calibration prior to each measurement.
The day-to-day repeatability of breath condensate pH in
control subjects and patients with bronchiectasis due to cystic
fibrosis in the unit has been reported as ±0.08 pH units [19],
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Induced sputum processing and analysis
Sputum was induced using incremental concentrations of 3, 4
and 5% hypertonic saline each delivered over 4 min, via an
ultrasonic nebuliser (DeVilblss Ultraneb 99; DeVilblss
Healthcare, Somerset, PA, USA), set at an output of
~-2.4mLmin' . Subjects were pre-treated with 25 mg salbuta-
mol via a nebullser. FEVi was monitored closely throughout
the test and the procedure was abandoned if FEVi decreased
by >20%. Sputum processing was performed using the
methods described by Pavord el al. [20]. A haematoxylin and
eosin stain was used for the cytospins. Sputum differential cell
counts were calculated from counting 400 inflammatory cells
and expressed as percentages of total inflammatory cell count.
When sputum eosinophil cell percentage was counted oil two
separate occasions in 12 sputum samples from subjects with
asthma, the correlation coefficient was r-0.98 (p<0.001). The
intra-observer 95% CI was +2.46%.
FEVi was measured to ERS standards using a standard
Vitalograph wedge-bellows spirometer.
Statistical analysis
For cross-sectional analysis between groups, an unpaired t-test
was used to determine whether differences observed were
significant. Correlatioas between RHML and other inflamma¬
tory markers in the asthmatic group were determined using a
Pearson correlation coefficient. Data that were not normally
distributed were log-normalised prior to correlation analysis.
The repeatability of RHML was assessed by calculating the
measurement error (intra-subject sd), using a method
described by Bland and Altman [21]. LeveLs of significance
were determined as p<0.05. Normally distributed data are
expressed as mean + so and non-normally distributed data are
expressed as median (interquartile range).
RESULTS
Study groups were well matched (table 1). FEVi (% predicted)
was significantly lower in stable asthma (82.7 + 26.9%) com¬
pared with controls (101.8+75%; p<0.01). For RHML mea¬
surement, the enthalpy of the iaspired air and the ventilator}'
pattern were closely matched between groups.
Study demographics and respiratory heat
HBB exchange data
Healthy control Stable asthma
Age yrs 41.6±13.1 44.7 ±14.6
Subjects n 18 23
Sex F/M 10/8 17/6
Height m 1.68+0.07 1.65 ±0.08
FEVi % pred 101.8±7.5 82.7 ± 26.9**
Enthalpy of inspirate J g'1 20.3± 1.6 21.9± 1.6
Minute ventilation L min"' 16.1 ±2.3 15.9 ±3.4
RHML J L1 91.9±4.5 98.1 ± 7.3**
Data are presented as mean ± so or n. F; female: M. male: FEVi: forced
expiratory volume in one second; % pred: % predicted. RHML: respiratory
healtF ard moisture toss. p<0.01.
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RHML was significantly elevated in patients with stable
asthma (98.1 + 73 JL'1) compared with control subjects
(91.9+ 4.5 J-L"1; p<0.01; fig. 2). Repeat measurements in nine
control subjects demonstrated a measurement error of
+ 1.6JL"1, giving a 95% CI of + 3.1 J-L*1. Repeat measure¬
ments in eight stable asthmatics showed a measurement error
for this test of 2.3 J-L"1, giving a 95% CI of + 4.6 J-L"1. In the
as tlimatic group, induced sputum collection was successful in
17 out of 23 patients. Sputum eosinophils were 6.8% (4.9-
18.6%), Fc.NOzw, 18.0 ppb (11.4-31.9 ppb) and EBC pH was
6.4 ±0.3.
Subgroup analysis of the asthma group revealed that there was
no significant difference in RHML between mild/moderate
persistent asthma and severe asthma (97.8 versus 98.3 J-L"1;
p—0.88). There was aLso no significant difference in RHML
between the 16 subjects who were on a regular LABA and
subjects who were not (983 ifcrsus 975 JL"1; p-^0.81).
Correlations between markers
There was a close correlation between RHML and logio
(sputum eosinophil percentage) in stable asthma (r—0.73,
p<0.0001; fig. 3) but no correlation with eNO (r^O.23), EBC
pH (r=-0.09), FEVi (r=-0.21) or FEVi % pred (r=-0.04). There
were no significant correlations between other markers.
DISCUSSION
An increase in RHML can be detected in patients with stable
but persistent symptomatic asthma. In these patients, there Is a
strong correlation between RHML and sputum eosinophilia, a
robust marker of asthmatic airway inflammation. This suggests
that the elevation in RHML in asthma Is due to increased
airway inflammation.
Original measurements of the thermal behaviour of airways in
lung disease first appeared in the Russian literature in the
1970s, with apparatus that integrated temperature changes
against volume of exhaled air [7J. Improved apparatus was
later used by the same group to demoastrate differences in
caloric output between control subjects and several patient
groups, including patients with bronchial asthma |8J.
However, in the present study, cooler inspirate, targeted
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(to engage the lower airway), and exhaled humidity measure¬
ment to quantify evaporative losses were used. These
differences make a direct comparison of the present results
with the previous study difficult.
As far as possible in a clinical setting, external factors that may
influence respiratory heat loss were controlled. Inspiratory
conditions were well controlled across groups and ventilatory
pattern was well matched during each test Minor differences
in respiratory pattern were corrected for by expressing RHML
per volume of expired air.
Drugs used in the treatment of asthma may have conflicting
effects on airway mucosal blood flow, potentially confounding
this measurement Inhaled corticosteroids are vasoconstrictors,
whereas (L-agonists are vasodilators. Corticosteroids have
been reported to reduce airway mucosal blood flow following
2 weeks' treatment [22j. This Is likely to reflect a reduction in
inflammation-related vascularity. The acute effect of inhaled
corticosteroids on bronchial blood flow is reported to be a
more transient vasoconstriction that Is maximal at 30 min and
has disappeared by 90 min [23J. In the context of the present
study, the observed increase in RHML was seen despite
potential confounding background vasoconstrictor effects of
inhaled steroids. In contrast, salbutamol is reported to have a
vasodilatory effect on the airway vasculature that may lead to
an increase in respiratory heat loss [24J. Nebulised salbutamol
can increase airway mucosal blood flow and breath-tempera¬
ture gradients in control subjects, although this effect Is not
apparent in asthmatic patients who already have a higher
baseline mucosal blood flow [23, 25j. There was no significant
difference between patients taking a LABA and those not (983
versus 97.5 J L*1; p—0.81). It Is unlikely that LABA exerted an
effect on RHML values. Patients withheld inhalers for >12 h
prior to testing, so it seems unlikely that the observed changes
were due to asthma medication.
The possible effect of differences in work of breathing on
RHML should be considered. However, there was no correla¬
tion between the severity of asthma, measured by FEVi %
pred, and RHML. Patients who have a higher work of












FIGURE 2. Respiratory heat ard moisture loss (RHML) in healthy control
subjects (n=18) ard patients with stable asthma (n=23). p =0.007.
FIGURE 3. Correlator between respiratory heat ard moisture loss (RHML)
ard sputum eosirophil percentage in stable asthma (n=17; r=0.73. p<0.001).
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The link between RHML and sputum eosinophil percentage is
an intriguing and novel correlation between a biophysical and
a cellular marker. Monitoring sputum eosinophil percentage
has been reported to have a positive impact on preventing
asthma exacerbations when compared with conventional
assessment of asthma in a randomised controlled trial [26]. A
similar impact has not been demonstrated with other non¬
invasive markers of airway inflammation so far.
RHML did not correlate with FEVi, FEVi % pred, eNO, or EBC
pH in stable asthma. Spirometry does not always correlate
consistentlywith markers of airway inflammation [27,28]. This
Is probably because inflammatory markers provide informa¬
tion on current airway inflammation, whereas spirometry
cannot distinguish between background structural damage or
remodelling and present inflammation. Furthermore, the
absence of a relationship between FEVi and RHML in the
asthmatic group reduces the possibility of the increase in
RHML being an airway calibre effect.
In mild untreated asthma, eNO has been reported to correlate
well with sputum eosinophils [29]. However, all patients in the
current stable asthma group were taking regular inhaled
corticosteroids, and in steroid-treated patients the relationship
between NO and sputum eosinophils Is much less pronounced
[27, 28]. These two markers vary in their response to inila led
steroid treatment [30, 31]. EBC pH has previously been
reported to correlate with sputum eosinophils in asthma by
Kostikas el al. [32]. Important differences in the present study
are that EBC samples were not deaerated prior to testing and
the subjects had more severe asthma.
The results of the present study demonstrate that respiratory
heat and moisture loss is elevated in a hospital-based
outpatient asthmatic population. Furthermore, a close correla¬
tion has been shown between sputum eosinophil percentage
and respiratory heat and moisture loss. Further investigations
may help to establish the effects of asthma medications on
respiratory heat and moisture loss and its utility in the
longitudinal assessment of patients with persistent asthma.
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